# **BMJ Open**

### Patients' values and preferences of the expected efficacy of hip arthroscopy for osteoarthritis: A protocol for a multinational structured interview-based study combined with a randomized survey on the optimal amount of information to elicit preferences

Journal:	BMJ Open
Manuscript ID:	bmjopen-2014-005536
Article Type:	Protocol
Date Submitted by the Author:	23-Apr-2014
Complete List of Authors:	Zhang, Yuqing; McMaster University, Clinicial Epidemiology and Biostatistics Tikkinen, Kari; Helsinki University Central Hospital and Clinical Research Institute HUCH Ltd., Department of Urology Agoritsas, Thomas; McMaster University, Department of Clinical Epidemiology and Biostatistics Ayeni, Olufemi; McMaster University, Department of Surgery Alexander, Paul; McMaster University, Department of Clinical Epidemiology and Biostatistics Imam, Maha; University of Waterloo, Pharmacy Yoo, Daniel; McMaster University, Faculty of Health Sciences Tsalatsanis, Athanasios; University of South Florida, Division of Evidence- based Medicine Djulbegovic, Benjamin; University of South Florida, Center for Evidencebased Medicine and Health Thabane, Lehana; McMaster University, Department of Clinical Epidemiology & Biostatistics Sch nemann, Holger; McMaster University, Dept. of Clin. Epidemiology and Biostatistics Guyatt, Gordon; Mcmaster University, Clinical Epidemiology and Biostatistics
<b>Primary Subject Heading</b> :	Surgery
Secondary Subject Heading:	Surgery, Evidence based practice, Communication, Sports and exercise medicine
Keywords:	Patients' values and preference, Total Hip Arthroplasty, Orthopaedic & trauma surgery < SURGERY, Hip Arthroscopy, Patient Written Information, Decision Making
	Decision Making

SCHOLARONE<sup>™</sup> Manuscripts

4	Patients' values and preferences of the expected efficacy of hip arthroscopy for
1 2 3	osteoarthritis: A protocol for a multinational structured interview-based study combined with a randomized survey on the optimal amount of information to elicit preferences
4 5 6 7 8 9	Yuqing Zhang, Kari A.O. Tikkinen, Thomas Agoritsas, Olufemi R. Ayeni, Paul Alexander, Maha Imam, Daniel Yoo, Athanasios Tsalatsanis, Benjamin Djulbegovic, Lehana Thabane, Holger Schünemann, Gordon H. Guyatt.
10 11 12 13	Yuqing Zhang, doctoral candidate, Department of Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main St., Hamilton, ON, Canada, L8S 4K1, e-mail Madisonz1220@gmail.com.
14 15 16 17	Kari A.O. Tikkinen, <i>post-doctoral fellow</i> , Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; and Department of Urology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
18 19	Thomas Agoritsas, <i>research fellow</i> , Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
20 21 22	Olufemi R. Ayeni, <i>consultant orthopaedic surgeon</i> , Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, ON, Canada.
22 23 24	Paul Alexander is doctoral candidate, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
25 26 27 28	Maha Imam, student, Faculty of Pharmacy, University of Waterloo, Kitchener ON Daniel Yoo, student, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. Athanasios Tsalatsanis, <i>assistant professor</i> , Division of Evidence-based Medicine, University of South Florida, Tampa, FL, USA.
29 30 31 32 33 34	Benjamin Djulbegovic, <i>distinguished professor</i> , Department of Internal Medicine, University of South Florida; and H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Lehana Thabane, <i>Professor/Associate Chair</i> , Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada.
34 35 36 37 38	Holger Schünemann, <i>Professor and Chair</i> , Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada.
39 40 41	Gordon H. Guyatt, <i>distinguished professor</i> , Department of Clinical Epidemiology and Biostatistics, and Medicine, McMaster University, Hamilton, ON, Canada.
42 43 44 45 46	<i>Correspondence to:</i> Gordon H. Guyatt, Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, guyatt@mcmaster.ca. Tel: (905)525-9140 x 22900FAX: (905)524-3841
47 48 49 50	<i>Keywords</i> Patients' values and preference, Total Hip Arthroplasty, Hip Arthroscopy, Osteoarthritis, Patient Written Information, Decision Making, Uncertainty
51 52 53 54 55	Word count: 5003
56 57 58	
59 60	1 1

## Abstract:

INTRODUCTION: Symptomatic hip osteoarthritis (OA) is a disabling condition with up to 25% cumulative lifetime risk. Total hip arthroplasty (THA) is effective in relieving patient's symptoms and improving function. It is, however, associated with substantial risk of complications, pain and major functional limitation before patients can return to full function. In contrast, hip arthroscopy (HA) is less invasive, and can postpone THA. However, there is no evidence regarding the delay in the need for THA that patients would find acceptable to undergo HA. Knowing patients' values and preferences (VP) on this expected delay is critical when making recommendations regarding the advisability of HA. Furthermore, little is known on the optimal amount of information regarding interventions and outcomes needed to present in order to optimally elicit patients' VP. 

METHODS AND ANALYSIS: We will perform a multinational, structured interview-based survey of preference in delay time for THA among patients with non-advanced OA who failed to respond to conservative therapy. We will combine these interviews with a randomized trial addressing the optimal amount of information regarding interventions and outcomes required to elicit preferences. Eligible patients will be randomly assigned (1:1) to either a short or a long format of health scenarios of THA and HA. We will determine each patient's VP using trade-off and anticipated regret exercises. Our primary outcomes for the combined surveys will be: 1) the minimal delay time in the need for THA surgery that patients would find acceptable to undertake HA, 2) patients satisfaction with the amount of information provided in the health scenarios used to elicit their VPs. 

ETHICS AND DISSEMINATION: The protocol has been approved by Hamilton
 Integrated Research Ethics Board (HIREB13-506). We will disseminate our study
 findings through peer-reviewed publications and conference presentations, and make
 them available to guideline makers issuing recommendations addressing HA and
 THA.

## BACKGROUND

### Osteoarthritis and surgical options

Osteoarthritis: Osteoarthritis (OA) is the most common form of chronic arthritis. Approximately 15% of men and women suffer from symptomatic OA[1], representing a large burden on patients, the healthcare system and society. Symptomatic hip OA is a particularly disabling condition with a cumulative lifetime risk of up to 25%. Conservative management of hip OA includes exercise, weight reduction, physical therapy and medications focusing on relieving symptoms, improving joint function, and optimizing quality of life[2]. Pharmacological and non-pharmacological interventions for severe OA are, however, substantially less effective than surgical treatment[3]. Consequently, most patients with severe hip OA eventually need total hip arthroplasty (THA)[3].

Total hip arthroplasty: With an aging population increasingly interested in staying physically active [4], the frequency and cost of THA continues to grow. Currently more than a half million THA procedures are performed annually in the UK and USA alone, and in 2010 the global market was estimated as high as 4.7 billion USD[5].

After failure of conservative treatment, THA is usually effective in relieving patient's symptoms and improving function, with more than 95% prosthesis survivorship at 10-year follow-up and more than 80% survivorship at 25-year follow-up[6, 7]. However, THA is also a major procedure, associated with substantial risk of complications, and with weeks of pain and major functional limitations before patients can return to full function. Therefore, patients and caregivers are interested in less invasive interventions that could postpone THA.

34 Hip arthroscopy: Less invasive interventions include arthroscopy, partial replacements, and bone-35 preserving techniques. They have shown varying success rates among OA patients[8]. Hip 36 37 arthroscopy (HA) is a new and the fastest growing procedure within orthopedic surgery[8]. Despite 38 the lack of high quality evidence, the number of HAs performed is expected to double in the United 39 States in 2013 compared to 2011[9]. HA is used to treat intra articular pathology of the hip, 40 including mild hip OA. Compared to THA it has the advantages of being minimally invasive and 41 42 having fewer complications [10]. Compared to THA, arthroscopy may help patients achieve higher 43 level of function more quickly with, over the short term less restriction on exercise. The expectation, 44 however, is that patients' underlying osteoarthritis will progress, and THA will ultimately become 45 necessary. The question then arises: what delay in the need for THA would warrant a patient 46 47 undergoing HA? This is a question of values and preferences.

#### 48 49

## <sup>49</sup><sub>50</sub> Measuring patients` values and preference

51 52 There are a number of techniques available for eliciting patients direct choices of which the 53 probabilistic version of the Threshold Technique (TT) also called probability trade-off (PTO) 54 exercise is widely used [11]. Following descriptive and probabilistic information regarding benefits 55 and harms associated with treatment choices - for example treatment A and B - in which the 56 relative benefits of treatment A versus B are large, the respondent is asked to choose one option. 57 58 Typically, patients will choose treatment A. The interviewer then presents an alternative situation 59 in which the relative benefits of A versus B are very small, and patients typically choose B. The 60

Page 5 of 44

### BMJ Open

interviewer than presents a small reduction in the probability of benefits, relative to the first scenario, for option A. If the patient continues to choose A, the next scenario presents a small increase in the benefits of A versus B relative to the second scenario. The process is repeated until

the indifference point between A and B is established (ping pong approach)[12].

4 5 6

1 2

Utility elicitation uses a very different approach, presenting health states and using one of a
variety of techniques to elicit the respondent's rating of the value of the health state on a scale
between death (typically 0) and full health (typically 1.0 or 100). The patients' responses are used to
build a decision model that calculates the treatment option that, given the patient's utilities,
achieves the maximum utility-adjusted outcome [13, 14].

14 Complementary approaches to assess patients' decision-making integrate emotional aspects of the 15 process. One such approach focuses on regret, an aversive emotion people experience when they 16 believe their current situation would have been better had they acted differently in the past[15, 16]. 17 In theory, regret is influenced by both intuitive, affect-based, and analytical, deliberative 18 19 processes[17, 18]. Reflecting on the anticipated regret of particular decisions (e.g. choosing A versus 20 B in the example above) may alert people to the choice that would be most likely to avoid this 21 aversive emotion[19, 20]. The anticipated regret theory-based approach preserves a rational 22 23 decision-making framework, while allowing anticipation of the effect of the decision on 24 emotions[21]. 25

Using both (direct choice) trade-off and anticipated regret exercises, our study will provide
 empirical evidence regarding the delay in the need for THA that patient would find acceptable to
 undergo HA.

# Amount of information presented to elicit patients' values and preference 33

34 The choices patients make are critically dependent on how the health scenario (HS) that 35 characterizes the processes and outcomes of the alternative management options (A and B in the 36 above – THA and HA in the current project) are presented. Research in marketing has addressed 37 some of the relevant issues. Information-processing framework[22] suggests that that there are 38 39 limits to the human ability to assimilate and process information, and that once these limits are 40 surpassed behavior becomes confused and dysfunctional[23]. Evidence suggests an inverted U-41 shaped relationship between information available and decision quality, in which individuals with 42 too little or too much information made poorer decisions than those with an intermediate amount of 43 44 information [24, 25]. 45

Other indirect evidence comes from research on written consent forms [26, 27]. Individuals often
 skim over consent forms for clinical trials in oncology if they are longer than 1,000 words or 4
 pages[28]. Twenty-seven oncology trials showed that patients obtain significantly higher objective
 knowledge when the consent form page count was seven or less [29].

52

In the area of pharmaceutical product choice, participants have had better understanding of shorter
 and easier information presentations[25]. One might expect, however, that if the information
 becomes too scanty, decision quality will deteriorate.

# 57 58 Patients' values and preferences on osteoarthritis surgical options

 $_{60}^{59}$  Given the existing evidence, both HA and THA represent reasonable choices for patients with non-

advanced OA. The choice may, however, be challenging. On one hand, HA is likely to achieve only transient improvement in function. On the other hand, the morbidity associated with THA is substantial.

Therefore, one of the key aspects in the choice between HA and THA is the duration of delay in the need for THA that patients may achieve with HA. If patients demand a delay time much greater than HA can realistically achieve, the procedure should seldom be considered. On the other hand, if patients would be satisfied with much shorter delay time, the procedure should be frequently considered. There is currently no empirical evidence addressing patients' values and preferences 10 regarding the delay they would demand to undertake HA. Knowing typical patients' values and 11 preferences regarding this expected delay is likely to be helpful for patients and health care 12 13 providers in the clinical encounter and for guideline panelists when making recommendations 14 regarding the advisability of HA. 15

The assessment of patients' values and preferences will be valid only to the extent patients receive sufficient accurate information on the outcomes of available treatment options presented in ways 18 that they can easily process. Thus far, only limited indirect evidence informs us on the optimal amount of information to provide in scenarios when eliciting patients' preferences.

Our study will provide direct empirical evidence on the optimal amount of information to provide when eliciting patients' values and preferences. It may also provide insight into the amount of information to provide in shared-decision making, although our study only indirectly addresses that issue.

#### 28 **OBJECTIVES** 30

1 2

3

4 5 6

7

8

9

16

17

19

20

21 22

23 24

25

26

27

29

37

41

47

49

53

54 55 56

31 General Objective: The purpose of this study is to improve the management of patients with non-32 advanced symptomatic hip osteoarthritis (OA) who failed conservative treatment by determining 33 their values and preferences regarding the choice between immediate total hip arthroplasty (THA) 34 35 versus hip arthroscopy (HA). 36

In the **Pilot stage** of our study, we will assess the following feasibility issues: (i) recruitment rate; 38 39 (ii) length of time to conduct the interview and fill out all the study measurements; (iii) potential 40 personnel and data management issues.

42 In **Study 1** – our primary objective is to determine the minimal delay time in the need for THA 43 surgery that patients would find acceptable to undertake HA (which we will refer to as the "delay" 44 45 time"). Secondary objectives include assessing patients' anticipated regret if the delay would differ 46 from their expectations, as well as potential determinants of their preference (e.g., age, gender, educational level, and socioeconomic status). 48

50 In **Study 2** – our objective is to assess the ease of understanding, optimal quantity of information, 51 and patients' satisfaction regarding alternative formats of the HSs used to elicit their preferences. 52

### **METHODS**

#### 57 Study design 58

9

10

### BMJ Open

### Pilot study

- In a pilot study, we will assess the following feasibility issues: (i) recruitment rate; (ii) length of
- <sup>3</sup> time to conduct the interview and fill out all the study measurements; (iii) potential personnel and
- data management problems in real-life setting. We will perform this study at the outpatient
   orthopedic clinic of the McMaster University Medical Center (Hamilton, ON, Canada).
  - Study 1: We will perform a multinational, cross-sectional, structured interview-based survey to assess the delay in THA that patients would demand to choose HA.
- Study 2: Within Study 1, we will conduct a randomized trial comparing a short version versus a
   long version of HA and THA health scenarios.
- <sup>14</sup> Table 1 shows the study flow.

Setting: The study will take place at McMaster University Medical Center, Hamilton, Canada; St.
 Michael's Hospital, Toronto, Canada; Hospital de Sant Pau, Barcelona, Spain; and Sorocaba
 Hospitals, São Paulo, Brazil.

## Study population

The population of interest consists of adults diagnosed with non-advanced hip OA. Table 2 presents
 the detailed inclusion and exclusion criteria.

## 2627 Recruitment strategy

We will prospectively identify consecutive patients confirmed with non-advanced hip OA referred for consideration of HA. The orthopedic surgeon will send a letter in advance of their visit to inform patients about our research project and the possibility of being approached by our research assistant (RA) for this study. The RA will then make initial contact with all the patients by phone to explain the purpose of the study. When the patients come to the orthopedic clinic, we will ask patients for their written informed consent.

## <sup>36</sup><sup>37</sup> Participants interview

38

### 39 Baseline information 40

We will document patients' age, gender, ethnicity, educational level (not completed high school;
completed high school only; some college/university; completed college or university), yearly income,
and their impression of the experience of close relatives or friends who have undergone HA or THA
(categorized as extremely dissatisfied; dissatisfied; neutral; satisfied; extremely satisfied, or
differing across individuals).

4849 Health scenarios

50

The health scenarios are designed to inform patients of the surgical options. Based on available evidence [30] we will include the following five sections in the HSs for THA and HA: [26] Brief introduction to the surgery; [31] Description of the surgical procedure; [iii] Post-operative recovery and rehabilitation; [iv] Expected benefits; [v] Risks and potential complications. *(See appendix: Script #1: Health scenarios)* 

57 58

59 The short versions have approximately 850 words and the long versions approximately twice the 60

number of words; both versions use the same sub-headings.

1 2

3

4

5 6

7 8

9

10

19 20

46

To ensure we present accurate estimates of benefits and risks of THA and HA to patients[32], conveyed in the most simple and easy-to-understand way possible, we applied a rigorous process to develop these health scenarios.

Firstly, we performed a search on PubMed to retrieve relevant content from systematic reviews, randomized control trials (RCT), and observational studies. Evidence from systematic reviews was preferred if available.

Secondly, we reviewed THA booklets from Brant Community Healthcare System, Hamilton Health
 Sciences, Joseph Brant Memorial Hospital, Niagara Health System, St. Joseph's Healthcare
 Hamilton, National Institute of Arthritis and Musculoskeletal, and Skin Diseases (NIAMS) to
 inform SCENARIO design and content. For both THA and HA, we also reviewed information from
 other sources such as the Informed Medical Decisions Foundations (IMDF) [33] and National
 Institute of Health for both THA and HA HSs (when available).

Thirdly, we considered the following strategies to increase the ease of understanding and readability of our scenarios[34]. We focused the material on key concepts with consistent and simple words aiming for 1–2 syllables[35, 36]. A clear topic sentence are used at the beginning of each sub-heading with following details and examples[37]. We also used conversational style with the second person point of view (i.e., "you")[37].

Finally, we revised our scenarios based on feedback from 15 orthopedic surgeons (8 of them commented on THA, and 7 of them commented on HA); from 2 focus group (3 patients in each group) and 4 individual interviews with a total of 10 patients (5 for each surgery) who had undergone THA or HA; and 5 physiotherapists.

For the Spanish and Portuguese part of the study, an experienced medical translator will undertake the initial translation. In each language, one clinical epidemiologist and one orthopedic surgeon, native in the non-English language and fluent in English, will check the translation and discuss potential revisions with the translator. After we obtain the Spanish and Portuguese versions, back translations will be performed and checked by the epidemiologist and the orthopedic surgeon, with further revisions to the Spanish and Portuguese versions if necessary.

4445 Randomization of the health scenarios

Participants will be randomized to receive the short format or long formats of the scenarios in coded
packages that the interviewer will open at the start of the interview. We will use central
randomization at McMaster University using an allocation ratio of 1:1 with random blocks size
(2,4,8).

We will ask participants to read hard copies of the corresponding health scenarios (short or long). At the end of the interview – i.e., after the trade-off exercise, anticipated regret exercise, and a check for consistency and understanding that we will describe subsequently – the RA will show patients in each group the version they have not yet seen and ask about their preferred format. If participants have more content questions regarding the scenarios, the RA will instruct the patient for

### Page 9 of 44

### **BMJ Open**

to ask the orthopedic surgeon for further assistance in the patient-doctor consultation after the interview.

### Trade off exercise

5 6 After participants have read the initial health scenario (short or long version), we will assess the minimum acceptable delay (delay time) in THA that patients would find acceptable to undergo HA. 7 8 We will use the following generic questions: "By how much longer should the arthroscopy postpone 9 the need for hip replacement surgery for you to consider the hip arthroscopy worthwhile? Would 10 you choose hip arthroscopy if it would delay the need for total hip replacement by [delay time in 11 months/year]?" We will offer a range of delay times, alternating between short and long times in a 12 ping-pong strategy, e.g.: 3 months - 12 years - 6 months - 10 years, etc. We will progressively 13 14 narrow the range of the alternatives offered as we repeat the exercise.

15 16

27

17 The lower bound of delay time offered (i.e. 3 months) is just below the anticipated least stringent 18 19 participants' demand and also corresponds to the shortest follow-up time in studies that evaluate 20 the efficacy of HA[38]. For the upper bound initially offered, the literature suggests that the most 21 optimistic estimate of the time which HA may delay THA is approximately 10 years[39]. If patients 22 23 are not satisfied with the upper boundary of the delay time – that is, they would demand a delay of 24 more than 12 years before they would undergo HA – there will be provision for them to express this 25 preference. 26

#### 28 Anticipated regret exercise 29

30 Following the trade-off exercise, we will assess participants' anticipated regret associated with 31 choosing or not choosing a treatment alternative. We will measure anticipated regret using a 100 32 mm visual analog scale (VAS) called the Feeling Thermometer (FT)[40], anchored at no regret (0) to 33 maximum regret (100). (Figure 1 anticipated regret VAS) 34 35

36 We will assess anticipated regret at five different time points (the patient personal threshold 37 determined during trade-off exercise, as well as two shorter and two longer options). For example, if 38 the patient chose 2 years as their shortest delay time, we will ask her: "How much regret would you 39 feel about choosing hip arthroscopy if you need to have a total hip replacement surgery after 12 40 41 months/1.5 years/2 years/3 years/4 years?. This process allows us to check for inconsistent 42 answers (see below). 43

#### 44 Blinding 45

50 51 52

53

57

46 Since this is a patient educational trial, the interviewers (data collectors) cannot be blinded. The 47 orthopaedic surgeons, patients (outcome assessors), and data analysts will be blinded to sequence of 48 giving HSs. 49

### **Outcomes**

54 Our primary outcome measures for the pilot stage regarding feasibility issues are the recruitment 55 56 rate, length of time to conduct the interview and fill out all the outcome measurements. We will explore the potential personnel and data management problems in the McMaster Medical center to 58 ensure the quality of the definitive stage of our study. We will note the number of participants 59 60

enrolled each week. The mean and standard error of the center's recruitment rate over recruitment period will be our study recruitment rate. We will also calculate the percentage of eligible patients who agree to participate. We will time the length of the interview, the length of finishing interviewers' administrated or patients' administrated questions.

We will consider recruitment feasible for a large study if we will be able to recruit two patients at McMaster Medical center per week (i.e., 100 subjects over 50 weeks). We considered the pilot stage (approximately 2 month) to be successful, and a large multicenter RCT to be feasible; if we successfully (i) recruit 20% of our estimated sample size; (ii) we will be able to finish the interview 10 and all the outcome assessment approximately one hour. (See table 3 for outcomes and 11 corresponding objectives). 12

14 We will modify our protocols in response to limitations with respect to excessive length of the 15 interveiew, difficulties with comprehension or ambiguities in the questions, and personnel or data 16 management problems identified in the pilot. 17

For Study 1, our outcomes are:

Primary outcome: the minimal delay in the need for THA surgery that patients would find acceptable to undertake HA (which we will refer to as the "delay time").

Secondary outcomes:

1 2

3 4

5 6

7

8

9

13

18 19

20 21

22

23 24

25 26 27

28

29

30

31 32

52

53 54

55

56

57 58

- Independent predictors of the primary outcome including age, gender, educational level, (i) and socioeconomic status.
- (ii) Patients' anticipated regret scores on a 100mm VAS at five different time points (the one patients chose in the trade-off exercise, and two shorter and two longer options).

33 For Study 2 our outcomes are: 34

35 Primary outcome: patients' satisfaction on the scenarios after reading the initial scenarios. 36 Interviewers will determine the degree of satisfaction participants place in the scenarios using a 7-37 point Likert-type scale with response options: completely dissatisfied, mostly dissatisfied, 38 39 somewhat dissatisfied, neither satisfied nor dissatisfied, somewhat satisfied, mostly satisfied, 40

completely satisfied. 41

Secondary outcomes: 42

- 1. Ease of understanding: we will assess participants impression of each of understanding of 43 44 each scenario using a 7-point Likert-type scale with response options: extremely hard, very 45 hard, hard, not easy not hard, easy, very easy, extremely easy. 46
- 2. Information quantity: we will ask participants to rate the quantity of the information 47 displayed in the initial presented scenario by a 7-point Likert-type scale with response 48 49 options: much too little, somewhat too little, slightly too little, about right amount of 50 information, slightly too much, somewhat too much, much too much. 51
  - 3. Patients' preference on length of format: After patients finishes reading both the long and short versions of scenarios we will ask them about their preference for the short or long version, using a 7-point Likert-type scale with response options: short version much better, short version somewhat better, short version little better, no preference, long version little better, long version somewhat better, long version much better.

#### 59 **Data collection** 60

5 6

7 8

9

10

11

16

21

23

24 25

26 27

28

### **BMJ Open**

A trained interviewer will collect all the outcomes by completing the case-report forms (CRFs) at the end of the interview. No follow-up and further data collection will be involved.

## Sample size calculation

Study 1:

Due to the paucity of similar studies in literature, we are unable to estimate the standard error (SE) of delay time precisely. If the data is normally distributed, 99.7% of the area under of the normal distribution curve lies within 3 standard deviations[41]. We assume the range of delay time (12) years) will be normally distributed. Therefore, we anticipate a SD of approximately 2 years. We 12 developed the sample size estimation table using the SD and varying the confidence interval 13 14 around the mean to obtain sample size using the formula below[42] (Table 4). 15

 $n = \frac{4z_{1-\frac{\alpha}{2}}^2\sigma^2}{L^2}$ 

N represents the sample size,  $\sigma$  represents the SE, L represents the confidence interval around the mean. 22

At the end of the pilot stage we will calculate the SE of delay time in the 20 patients as a reference point to modify our earlier sample size estimation for the definite study.

### Study 2:

29 Based on Cohen's rule of sums [43], we used "SD=0.5" to calculate the sample size to achieve a 30 medium effect size. With a sample size of 62 in each group the trial is powered to detect a medium 31 32 effect size of mean = 0.5 or larger given 80% power level and  $\alpha$  = 0.05 in a two-sided test. 33 Considering the result will be obtained immediately after the assessment and all outcomes will be 34 interviewer administrated, we anticipate no loss to follow-up. We also made a sample size 35 estimation table with different confidence intervals around the mean (Table 4). Sample size 36 37 calculation is performed using SPSS (Statistical Package for the Social Sciences) version 21.0 for 38 Windows. 39

40 After finishing the pilot stage of our study, we will compare the estimated sample size for study 1 41 42 and 2 and take the larger number as our final sample size for the combined studies. 43

#### 44 Data analysis and interpretation 45

46 Study 1 47

48

#### 49 Description of baseline characteristics: 50

We will present patients' age, gender, ethnical / cultural group, educational level, socioeconomic 51 status and medical history[44]. Means and standard deviations (SD) will be used to present 52 53 continuous variables and two-tailed T-test (or Mann-Whithey U test for non-normal distributions) 54 to detect significant differences (p<0.05) between group means. We will use proportions and 55 frequency tables to present categorical variables and a two-tailed Fisher's Exact test will be used to 56 57 detect statistically significant (p<0.05) differences between two groups.

58

59 *Primary and secondary outcome(s):* 60

We will assess the distribution of the mean delay time and represent it graphically using histogram(s). If the data is normally distributed we will present the mean delay time and SD. We will also estimate 95% confidence intervals of the mean respectively. If the data is skewed, we will present the mode, median, and interquartile range.

Multiple variable linear regressions will be undertaken to determine statistically independent predictors of the threshold of delay time. In this analysis, the delay time will be the dependent variable and the independent variables will be the previous experience of THA and HA in friends and family, age, gender, socioeconomic status, educational level.

After presenting the health scenarios and recording participants' response with both "trade off" and anticipated regret exercise, we will compare results between these two measurements of participants' values and preferences.

We have defined three possible patterns of inconsistent response (See table 5 Inconsistency checking). If the participants' answers fall into any of these patterns, interviewers will review participants' original answers without, however, implying that they must modify their original choices. If the participants confirm their original answers, interviewers will determine and record the reasons of participants' inconsistent choices based on participants' explanation. If patients, following review of the relation between their trade off and regret choices, desire to modify their chosen delay time, interviewers will repeat the trade-off exercise.

For the analyses above, we will determine whether the delay time differs between those with an
apparently high level of understanding and those who demonstrate any of the inconsistencies
depicted in Table 2. If we find an important discrepancy between the results of patients categorized
as understanding and not understanding, we will focus our primary analysis on the group of
patients who apparently have a high level of understanding.

Study 2

<sup>8</sup> Baseline characteristics description

We will summarize patients' age, gender, ethnical / cultural group, educational level, social economics status in a table.

Primary and secondary outcome(s):

Our primary outcome will be participants' satisfaction of the health scenarios assessed by a 7-point Likert scale. We will also visualize it by using histogram(s). We will conduct a two-sided student Ttest will to compare mean satisfaction scores and ease of understanding between the short and long scenarios. We will also calculate the mean difference and 95% confidence intervals.

For information quantity, we will present a histogram depicting the proportion of participants' choice in each category. We will apply 2 approaches to analyze information quantity at the first assessment. First, we will determine if the distribution between two groups differ by greater than chance with two-sided student T-test (if its normally distributed) or Mann-Whitney U test(if its not normally distributed). Second, using a chi-square test we will determine if the proportions of participants who choose "about the right amount of information", in comparison to those who choose other response options, differ between groups. 

3

4

5 6

7

**BMJ Open** 

We will use 2 approaches to compare participants' preferences for the short versus long formats after showing patients both scenarios. First, we will treat the outcomes on the 7-point scale as multinomial ordered outcomes. We will analyze the result using Mann-Whithey U test. Second, we will use a more conservative approach and compare the proportions of participants who prefer the short format to the proportion of participants who have either no preference or prefer the long format by using a chi-square test. (Table 3: Summary of analysis plan).

## <sup>8</sup> ETHICAL AND DISSEMINATION

This study will be performed in accordance with established guidelines for research involving 10 11 human patients. The proposed study does not pose any safety risks to participating patients. The 12 protocol has received Research Ethics Board approval at Hamilton Health Sciences (McMaster 13 University Medical Centre) and will be submitted for approval at the other participating sites. The 14 research objectives and study intervention will be explained to the patient verbally and in writing 15 16 in easily comprehensible language. Written informed consent will be obtained from all patients. 17 Patients will be informed of their right to ask for further information at any time and to withdraw 18 from study without prejudice to their future care. In the unlikely event that participants find 19 considering the above scenarios upsetting, the interview will be immediately stopped and support 20 21 offered. We will ensure confidentiality of patient data by anonymizing patients by a unique 22 numerical identifier. Records will be stored in a secure database. Access to the database will be 23 restricted to those directly involved in the design, implementation, and analysis of the data. No 24 patient will be identifiable in any publication arising from the study. 25 26

The reporting of Study 1 will conform to the STROBE statement [45], and reporting of Study 2 to the CONSORT statement[46]. We will disseminate our study findings widely through peer-reviewed publications and conference presentations, and make them available to guideline makers issuing recommendations on HA and THA.

# <sup>33</sup> <sup>34</sup> **DISCUSSION** <sup>35</sup>

## <sup>36</sup>37 Strength and weaknesses

The design of our study has several strengths. Firstly, we have incorporated the anticipated regret model as a new method in the exploration of patients' values and preferences. Based on considerable previously published theoretical work by members of our research team [47, 48] our study will be the first to evaluate and compare its results with other methodologies. The comparison will include differences in decisions, inconsistencies, and understanding.

Secondly, in developing health scenarios we obtained input from patients who have undergone both
total hip replacement and HA and surgeons who have expertise on total hip replacement and HA.
These processes ensured the accuracy of our health scenarios that will be used in the study.

49 50

51 Thirdly, we will be the first to explore the association between influence from family and friends' 52 previous experience on patients' values and preferences on the minimal delay time in the need for 53 54 THA surgery that patients would find acceptable to undertake HA. Indirect evidence suggests 55 friends or family member's medical advice may influence patients' preference on medical decisions. 56 Men, African-American men in particular, are more inclined to discuss their medication concerns 57 and to seek medical advice from trusted friends more frequently than women[49]. Women are more 58 59 often inclined to solicit medical advice from their family members. Identifying the factors that may 60

influence patients' preferences could provide valuable explanations for the variation on patients' values and preferences in future research. Knowing patients' previous perception on certain treatment options can help clinicians to explain certain things more clearly and makes clinical consultation more efficient.

Fourthly, we will check for consistency in the participants' choice on their threshold of how long HA can delay THA they think it worthwhile proceeding. If participants have discrepant answer between the trade off and anticipated regret exercise we will provide them the opportunity to change their responses. Interviewers will test patients` understanding of the information presented using standardized questions and rate respondents understanding based on their judgment. This ensures the validity of patients' values and preference elicitation. 


#### Implications

6

Although there is increasing awareness regarding shared decision-making and patient centered care, the explicit consideration of values and preferences in the care of individual patients and in the recommendations made by clinical practice guidelines remains limited [31-36]. 

Given the existing evidence, the choice between HA and THA for patients with non-advanced OA is challenging. The research outlined in this protocol will provide explicit, quantitative expressions of patients' valuations of their expected delay of HA on THA. This information will alert clinicians to this issue and may provide guidance in their interactions with patients. It will certainly provide crucial information for guideline developers making recommendations for clinical practice. Identifying the factors that may influence patients' preferences could provide insight into variations in broader perspective of patients' values and preferences in future research. 

Our protocol also addresses some of the limitations of the previous studies in the field of medical written information regarding using adequate amount of information in patients' values and preference assessment. Results will have implications for clinical practice in terms of providing patients' with the right amount of information in the shared decision-making process. 







Table 2 metusion and Exclusion enterna					
Inclusion criteria	Exclusion criteria				
(i) Patient is at least 40 years old	(i) Patient has a history of prior hip				
	surgery				
(ii)Patient diagnosed by X-ray or magnetic	(ii) Patient is unable of complete the				
resonance imaging (MRI) with mild or	research tasks due to cognitive				
moderate (grades 1 and 2) OA based on	impairment or language barriers				
Tonnis classification of OA[ <b>50</b> ]					
Grade 0: No signs of OA.					
Grade 1: Mild: increased sclerosis, slight					
narrowing of the joint space, no or slight					
loss of head sphericity.					
Grade 2: Moderate; small cysts, moderate					
narrowing of the joint space, moderate loss					
of head sphericity.					
Grade 3: Severe: large cysts, severe					
narrowing of obliteration of the joint space,					
severe deformity of the head.					
(iii) Patient has history of failed	(ii) Patient is unwilling or unable to				
conservative management	provide informed consent.				
(iv) Patient provides a written informed					
consent.					

### **Table 2 Inclusion and Exclusion criteria**

]





### Table 3: Summary of analysis plan

Study	Objectives	Outcomes	Predictors	Hypothesis	Outcome Measure	Methods of Analysis
Pilot stage						
	Determine feasibility	a) Recruitment rate		2 subjects/week	Subjects per week	
		b) Time to conduct the interview and finish all the measurement		1hour would be optimal	Interview duration	
		c) Patients attrition		Less than 5%	Patients attrition rate	
Study one: Interview Study	<u>Primary</u>	a) Delay time	age, gender, ethnicity, educational level, social economics status and medical history		Trade-off exercise	Normally distributed: mean delay time +SD; mean delay time and confidence interval If data is skewed: mode, median, and interquartile range
	<u>Secondary</u>	a) Patients' anticipated regret scores			100mm Visual Analog Scale	T-test
Study two: RCT	<u>Primary</u>	a) Patients' satisfaction on the HSs		Higher satisfaction on short version	7-point Likert type scale	T-test
	<u>Secondary</u>	a) Understandability		Both have rated as 5/7	7-point Likert type scale	T-test
]		b) Information quantity		Short will be rated as 4; Long will be rated as 5;	7-point Likert type scale	T-test
		c) Patients' preference on length of format		Prefer short version	7-point Likert type scale	T-test or Mann Whitney U test
Sensitivity Analyses		Patients' satisfaction on the HSs		Higher satisfaction on short version	7-point Likert type scale	Mann–Whitney U test
		Comprehensibility		Both have 5/7	7-point Likert type scale	Mann–Whitney U test
		Information quantity		Short will be 4; Long will be 5;	7-point Likert type scale	Mann–Whitney U test
		Patients' preference on length of format		Prefer short version	7-point Likert type scale	Mann–Whitney U test

### Table 4: Sample size estimation tables

Study	œ	SD	<i>L</i> (width of CI -years)	Sample size
Study one	0.05	2	0.5	246
			1	62
			2	16
			2	16

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

### Table 5: Inconsistency checking

Definitions/criteria of inconsistencies	Explanations and Examples
(i) Participants anticipate regret score is higher when delay in need for THA is longer than it is at their threshold of delay time.	In the example we give that measures anticipated regret scores: we set the 5 time points as A (12 months), B (1.5 years), C (2 years), D (3 years) and E (4 years). The participant chose 2 years as the shortest delay time at which he/she can accept for processing HA. Then they placed scores 60 to represent their regret on VAS at 12months but scores 90 to represent his/her regret at 1.5years. In other words, the regret scores "r" on VAS shows: rA <rb, or="" or,="" rb<rc,="" rc<rd,="" rd<re.<="" th=""></rb,>
(ii) Participants anticipate substantial regret although the HA would delay THA longer than their threshold of delay time.	We define substantial as the anticipated regret score on VAS at the time point that they chose in the "trade off" exercise or any longer delay time point is bigger than (30) on the 100 VAS scale. The participant chose 2 years as the shortest delay time at which they can accept for processing HA. Then they still placed scores 60 to represent their regret on VAS at 2years, 3 years or 4years. In other words, the regret scores "r" on VAS shows: rC>0, OR rD>0, OR rE>0.
(iii) Patients do not anticipate any regret when delay in THA end up being shorter than what their threshold of delay time.	Comparing to the time point that participants chose in the "trade off" exercise, the anticipated regret score on VAS at any shorter delay time point is equal to (0). For example, the participant chose 2 years as the shortest delay time at which they can accept for processing HA. Then they place scores 0 to represent their regret on VAS at 12months and 1.5 years. In other words, the regret scores "r" on VAS shows: rA=0, OR rB=0.

We would like to thank Matti Seppänen, Teppo Järvinen, Daniel Nightingale, Darryl Yardley, Gloria Preston, Colleen Cupido, for their feedbacks on our Health Scenarios. We would also like to thank Qi Zhou (Department of Clinical Epidemiology and Biostatistics, McMaster University) for her help on planning the statistical analyses and Peggy Austin, CCRA for her help on operating the study.

**Contributors:** YZ, KAOT, TA and GHG designed the study. YZ drafted the manuscript, with substantial inputs from TA, KAOT and GHG. DY, AT and KAOT drafted the trade-off exercise and regret exercises. BDB, GHG provided feedback on the regret exercises. MI and YZ drafted the HSs. PA, KAOT, YZ conducted the interview to test HSs. All authors contributed to the refinement of the study protocol and approved the final manuscript. GHG is the principal investigator of the study.

### Funding: None

### Competing interests: None

**Ethics approval:** The protocol has been approved by Hamilton Integrated Research Ethics Board (HIREB13-506)

**Provenance and peer review:** Not commissioned; internally peer reviewed.

**Open Access:** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.

### **Reference:**

- 1. Woolf, A.D. and B. Pfleger, *Burden of major musculoskeletal conditions.* Bull World Health Organ, 2003. **81**(9): p. 646-56.
- 2. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum, 2000. **43**(9): p. 1905-15.
- 3. Brandt, K.D., *Non-surgical treatment of osteoarthritis: a half century of "advances"*. Ann Rheum Dis, 2004. **63**(2): p. 117-22.
- 4. Rath, E., O. Tsvieli, and O. Levy, *Hip arthroscopy: an emerging technique and indications.* Isr Med Assoc J, 2012. **14**(3): p. 170-4.
- 5. Chen, A., et al., *The Global Economic Cost of Osteoarthritis: How the UK Compares.* Arthritis, 2012. **2012**: p. 698709.
- 6. Kurtz, S., et al., *Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030.* J Bone Joint Surg Am, 2007. **89**(4): p. 780-5.
- 7. *7th annual report*, in *National Joint Registry for England and Wales*. 2010, National Joint Registry: Hemel Hempstead.
- 8. Kenney, N.A. and K.W. Farmer, *Minimally invasive versus conventional joint arthroplasty.* PM R, 2012. **4**(5 Suppl): p. S134-40.
- 9. DK, M. *Hip arthroscopy: Update, advances, and future applications.* AAOS Now, 2011. **5**.
- 10. Griffiths, E.J. and V. Khanduja, *Hip arthroscopy: evolution, current practice and future developments.* Int Orthop, 2012. **36**(6): p. 1115-21.
- 11. HA., L.-T., *Threshold technique*. Kattan MW, ed. Encyclopedia of Medical Decision Making. . 2009, Thousand Oaks,CA: Sage Publications. 4.
- 12. Llewellyn-Thomas, H.A., et al., *Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia.* Med Decis Making, 1996. **16**(3): p. 262-82.
- 13. Ubel, P.A. and G. Loewenstein, *The role of decision analysis in informed consent: choosing between intuition and systematicity.* Soc Sci Med, 1997. 44(5): p. 647-56.
- 14. GW., T., Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Econ Planning Sci, 1976. **10**(129): p. 36.
- 15. Zeelenberg, M., *The use of crying over spilled milk: A note on the rationality and functionality of regret.* Philosophical Psychology, 1999. **12**(3): p. 325-340.
- 16. Zeelenberg, M., *Anticipated regret, expected feedback and behavioral decision making.* Journal of Behavioral Decision Making, 1999. **12**(2): p. 93-106.
- 17. D., K., *Maps of bounded rationality: psychology for behavioral economics.* The American Economic Review, 2003.(93): p. 1449-1475.
- 18. JSBT., E., *Hypothetical thinking: Dual processes in reasoning and judgement.* 2007, New York: Psychology Press.
- 19. I, S., *The influence of anticipating regret and responsibility on purchase decisions.* J Consumer Res, 1992. **19**: p. 105-118.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

### **BMJ Open**

	BMJ Open			
20.	Zeelenberg M, P.R., A theory of regret regulation 1.0 J Consumer			
	nology, 2007. <b>17</b> : p. 3-18.			
21.	Tsalatsanis, A., et al., <i>A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-makin</i> BMC Med Inform Decis Mak, 2010. <b>10</b> : p. 51.			
22.	Bettman., J., <i>Information processing models of consumer behavior.</i> J Market Res, 1970. <b>7</b> : p. 6.			
23.	Jacob Jacoby, D.E.S., and Carol A. Kohn., <i>Brand Choice Behavior As a Functi</i> of <i>Information Load: Study Ii (Abstract)</i> . Advances in Consumer Research, 1974. <b>01</b> : p. 3.			
24.	Hahn, M., R. Lawson, and Y.G. Lee, <i>The effects of time pressure and informa load on decision quality.</i> Psychology and Marketing, 1992. <b>9</b> (5): p. 365-37			
25.	Young, D.R., D.T. Hooker, and F.E. Freeberg, <i>Informed consent documents: increasing comprehension by reducing reading level.</i> IRB, 1990. <b>12</b> (3): p. 1			
26.	Comprehensive Working Group on Informed Consent in Cancer Clinical Tria for the National Cancer Institute: Recommendations for the Development of Informed Consent Documents for Cancer Clinical Trials 1998 [cited 2013 April 9th].			
27.	OHRP Informed Consent Frequently Asked Questions 2008 [cited 2013 Ap 9th]; Available from: <u>http://www.hhs.gov/ohrp/informconsfaq.html</u> .			
28.	Sharp, S.M., Consent documents for oncology trials: does anybody read thes things? Am J Clin Oncol, 2004. <b>27</b> (6): p. 570-5.			
29.	Beardsley, E., M. Jefford, and L. Mileshkin, <i>Longer consent forms for clinica trials compromise patient understanding: so why are they lengthening?</i> J Cl Oncol, 2007. <b>25</b> (9): p. e13-4.			
30.	Soever, L.J., et al., <i>Educational needs of patients undergoing total joint arthroplasty.</i> Physiother Can, 2010. <b>62</b> (3): p. 206-14.			
31.	Alonso-Coello, P., et al., <i>Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol.</i> E Pregnancy Childbirth, 2012. <b>12</b> : p. 40.			
32.	Schunemann, H.J., et al., <i>A comparison of narrative and table formats for presenting hypothetical health states to patients with gastrointestinal or pulmonary disease.</i> Med Decis Making, 2004. <b>24</b> (1): p. 53-60.			
33.	Informed Medical Decisions Foundations 2013; Available from: http://www.informedmedicaldecisions.org/.			
34.	Pierce, L.L., <i>How to choose and develop written educational materials</i> . Reha Nurs, 2010. <b>35</b> (3): p. 99-105.			
35.	Aldridge, M.D., <i>Writing and designing readable patient education material</i> . Nephrol Nurs J, 2004. <b>31</b> (4): p. 373-7.			
36.	Monsivais, D. and A. Reynolds, <i>Developing and evaluating patient educatio</i> <i>materials.</i> J Contin Educ Nurs, 2003. <b>34</b> (4): p. 172-6.			
37.	Turnbull, A., <i>How nurses can develop good patient information leaflets.</i> Nur Times, 2003. <b>99</b> (21): p. 26-7.			
38.	Stevens, M.S., et al., <i>The evidence for hip arthroscopy: grading the current indications</i> . Arthroscopy, 2010. <b>26</b> (10): p. 1370-83.			


- 39. McCarthy, J.C., et al., *What factors influence long-term survivorship after hip arthroscopy?* Clin Orthop Relat Res, 2011. **469**(2): p. 362-71.
- 40. Green, C., J. Brazier, and M. Deverill, *Valuing health-related quality of life. A review of health state valuation techniques.* Pharmacoeconomics, 2000. **17**(2): p. 151-65.
- 41. G.Bluman, A., *Elementary Statistics: A step by step approach*. fifth edition ed. 2010: McGraw Hill.
- 42. Blalock, H.M., *Social Statistics*. 1979, New York: McGraw-Hill.

- 43. Cohen, J., *A power primer*. Psychol Bull, 1992. **112**(1): p. 155-9.
- 44. Hawker, G.A., *Who, when, and why total joint replacement surgery? The patient's perspective.* Curr Opin Rheumatol, 2006. **18**(5): p. 526-30.
- 45. Vandenbroucke, J.P., et al., *[Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration].* Gac Sanit, 2009. **23**(2): p. 158.
- 46. Tfelt-Hansen, P.C., *CONSORT recommendations in abstracts of randomised, controlled trials on migraine and headache.* J Headache Pain, 2011. **12**(5): p. 505-10.
- 47. Alolabi, B., et al., *The development of a decision aid to elicit treatment preferences for displaced femoral neck fractures.* Indian J Orthop, 2012. **46**(1): p. 22-8.
- 48. Bryant, D., E. Bednarski, and A. Gafni, *Incorporating patient preferences into orthopaedic practice: should the orthopaedic encounter change?* Injury, 2006. **37**(4): p. 328-34.
- 49. Vieder, J.N., et al., *Physician-patient interaction: what do elders want?* J Am Osteopath Assoc, 2002. **102**(2): p. 73-8.
- 50. D., T., Congenital dysplasia and dislocation of the hip in children and adults. 1987, New York: Springer

### **Total Hip Replacement for Hip Osteoarthritis (SHORT)**

### **Introduction**

Hip replacement is а surgery that aims to relieve arthritis pain. stabilize and improve the function of your hip. The most common cause for the pain is osteoarthritis (OA). Cartilage, which is the rubbery tissue that cushions your bones and joints, can break down and wear away. As a result. the bones rub together, causing pain, swelling, and stiffness.



\*ADAM

The surgeon will remove the old hip joint and put in a new joint. If other treatments such as physical therapy, pain medicines, and exercise have not helped, then hip replacement surgery might be an option for you.

### **Procedure:**

- The anesthetist will put you to sleep if you request it, and you will not feel any pain during surgery.
- After you receive anesthesia, your surgeon will open up your hip joint and does the following:
  - Removes the damaged ball from the thighbone and cleans out the socket.
  - Replaces the natural joint with an artificial ball and socket.
- > The surgery usually takes 1 to 3 hours.

A metal ball and stem are inserted in the femur and a plastic socket is placed in the enlarged pelvis cup



\*ADAM

### **Benefits:**

> Main benefit:

### BMJ Open

- Relief of symptoms, including reduced pain, increased mobility and/or regained ability to perform activities of daily living.
- The above improvements depend on the severity of your OA and other preexistent diseases.
- > Post-operative mobility:
  - Most of you will have an increased range of movement 3 months after surgery. About 51 in 100 (51%) of you will not need an aid to walk and will be able to move your hip more than 160 degrees.
  - About 77 in 100 (77%) of you will be able to walk without support, 21 in 100 (21%) will use a cane, and 2 in 100 (2%) will use crutches (Data from patients average age of 80; range, 56-98 years old) after 1 to 2 years.
- > Pain relief:
  - About 87 to 91 in 100 (87%-91%) of you will have great or complete pain relief, and 9 to 13 in 100 (9%-13%) of you will experience an unfavorable long-term joint pain after the procedure from 3 months to 5 years (Data from patients average age of 69 years old).
- > Sleep:
  - Your sleeping quality will improve significantly 10 weeks after surgery.
- Determinants regarding home management, mobility, and work will considerably improve after 3 months.

### **Recovery:**

- > Management:
  - You may have great deal of pain requiring painkillers within the first days.
  - You may have some pain for up to 2-3 weeks and the pain may persist for 3 months.

### Rehabilitation:

- You will have severe mobility restrictions and the types of restriction will depend on the specific procedure of your surgery. You will need a walker for the first days to weeks; then a cane or crutches for weeks up to 3-6 months.
- You will not be able to bend your hip over 90 degrees for 3 months.
- Physical therapy is an important part of the recovery process. You will work with a physical therapist to develop an exercise and rehabilitation program while your stay in the hospital.

- The rehabilitation program generally includes exercises to stretch and strengthen the muscles surrounding the hip joint, as well as training in activities of daily living.
- $\circ~$  Most of you will be able to resume your activities of daily living within 3 to 6 months.

### **Long-term outlook:**

- > 90 out of 100(90%) of your hip replacements will last longer than 10 years.
- 85 out of 100(85%) of your hip replacements will last longer than 20 years.
- Over the course of 15 to 20 years, the artificial hip joint will loosen and you may need a second replacement.

### **Possible Risks and complications:**

- In 6 months post operation, about 30 in 100 (30%) of you will have at least one complication.
- While some complications can be a bit more serious, most can be treated successfully.
- Urine retention: About 20 to 35 in 100 of you (20-35%) will experience it.
- Infections: About 1 in 100 of you (1%) will develop a wound or deep infection after the operation.
- ➤ Death: 0.3 out of 100(0.3%) will die.
- Blood clots in the legs or pelvis: About 0.5 in 100 (0.5%) of you may experience it before hospital discharge.
  - The blockage causes pain and swelling in the affected leg that typically gets better in about a month.
- Blood clots in the lungs: About 0.9 in 100(0.9%) during the first 6 months.
  - This leads to shortness of breath, sometimes severe, which with anticoagulant treatment resolves in about 2 weeks. Anticoagulant treatment will be used for 3 months.
- $\succ$  Dislocation of the hip: About 4 in 100(4%) at the first 6 months.
  - You could experience sharp, pain that become worse if the joint has moved. Your orthopedic surgeon will pull on the leg to reposition the hip within the socket under anesthesia.
- ➢ Nerve damage: About 1 to 3 in 100 (1%-3%).

60

• If there is nerve damage, you will have decreased feeling or loss of strength in the leg, foot or ankle area.


Different leg lengths: Less than 1 in 100(1%) of you will need another operation because one leg is longer than the other.

### **Total Hip Replacement for Hip Osteoarthritis (LONG)**

### **Introduction**

Hip replacement is a surgery, also called Total Hip Arthroplasty,

which aims to relieve arthritis pain, improve function, and make your hip more stable. The most common cause for the pain is osteoarthritis (OA), and the reason for OA is unknown. Cartilage, which is the rubbery tissue that cushions your bones and joints, can break down and wear away. As a result, the bones together, causing rub pain, swelling, and stiffness. During the operation, the surgeon will remove the old hip joint and put in a new



<sup>\*</sup>ADAM

joint. If other treatments such as physical therapy, pain medicines, and exercise have not helped, then hip replacement surgery might be an option for you.

### **Procedure**

- The hip joint is made up of two major parts. One or both parts may be replaced during surgery.
  - The hip **socket**, which is cup-shaped, and sits in the pelvis.
  - The **ball**, which is the upper end of the thighbone (called the femoral head).
  - > The new hip that replaces the old one is made up of these parts:
    - $\circ~$  A socket, which is usually made of strong metal.
    - A liner, which fits inside the socket and usually, is made of either plastic, ceramic, or metal.
    - A metal or ceramic ball that will replace the top of your thighbone.
    - $\circ~$  A metal stem that is attached to the thighbone to make the joint more stable.

- > If you would like to sleep during the surgery, the anesthetist will put you in sleep, and you will not feel any pain during surgery.
- $\succ$  Anesthesia:

- You will not feel any pain during surgery due to one of two types of anesthesia that you will receive
- General anesthesia: you will be 'asleep' (unconscious) for the procedure and not have any memory of the surgery.
- Regional anesthesia: local anesthesia will be put in your lower back to make your body numb so you won't feel the procedure. Although you will still be awake and aware of the procedure the anesthesiologist can give you sedation medication to make you quite sleepy so you aren't anxious and mostly unaware of the procedure.
- > After you receive anesthesia, your surgeon will make a surgical cut to open up your hip joint. Then you surgeon will:
  - Cut and remove the head of the thighbone.
  - Clean out your hip socket and remove the rest of the cartilage and damaged bone.
     A metal ball and stem are inser
  - Put the new hip socket in place, then insert the metal stem into your thighbone.
  - Place the correct-sized ball for the new joint.
  - Secure all parts with cement.
  - Repair the muscles and tendons around the new joint.
  - Close the surgical cut.
- The surgery usually takes 1 to 3 hours.

A metal ball and stem are inserted in the femur and a plastic socket is placed in the enlarged pelvis cup



(MedlinePlus, 2012)

\*ADA.M.

### **Benefits**

- > Main benefit:
  - Relief of symptoms, including reduced pain, increased mobility and regained ability to perform activities of daily living.
  - Function improvement and pain relief are depending on the severity of your OA and other preexistent diseases.
- > Mobility postoperatively:
  - Most of you will have an increased range of movement 3 months after surgery. About 51 in 100 (51%) of you will not need

 assistance to walk and will be able to move your hip more than 160 degrees.

- About 49 in 100 (49%) of you will require assistance to walk and will be able to move your hip less than 160 degrees after 3 months.
- About 64 in 100 (64%) of you will be able to walk longer distances compare to pre-operatively after 3 months (Data from patients age 55-84 years old).
- About 77 in 100 (77%) of you will be able to walk without support, 21 in 100 (21%) will use a cane, and 2 in 100 (2%) will use crutches (Data from patients average age of 80; range, 56-98 years old) after 1 to 2 years.
- > Pain relief:
  - About 87 to 91 in 100 (87%-91%) of you will have great or complete pain relief, and 9 to 13 in 100 (9%-13%) of you will experience an unfavorable long-term joint pain after the procedure from 3 months to 5 years follow-up (Data from patients average age 69 years).
  - About 25 in 100 (25%) of you will only have occasional pain 3 months after operation.
- > Sleep:
  - Your sleeping quality will improve significantly 10 weeks after surgery.
- > Psychological improvements:
  - Your psychosocial quality of life will improve regarding social interaction, communication, alertness behavior, and emotional behavior immediately and 6 months after the operation.
- Factors such as home management, mobility, and work will considerably improve after 3 months.

### **Recovery:**

- > Management:
  - After surgery, you may experience a great deal of pain within the first days and you may need to take painkillers.
  - You may be given pain medication intravenously using a pump (patient-controlled-analgesia).
  - $\circ~$  You may have some pain for up to 2-3 weeks and the pain may persist for 3 months.

- You are likely to have problems with constipation from painkillers in the first weeks after surgery.
- $\circ$  You will be given an antibiotic to prevent infection.
- You may also be given a medication or compression boots and stockings to prevent blood clots in the legs.

### > Rehabilitation:

- You will have severe mobility restrictions and the types of restriction will depend on the specific procedure of your surgery. You will need a walker for the first days to weeks; then a cane or crutches for weeks to 3-6 months.
- You will not be able to bend your hip over 90 degrees for 3 months. This means you cannot bring your knee up to your chest and you also cannot bend forward at the hip past 90 i.e. if tying your shoes.
- You may also have restricted adduction (moving your leg past midline) and any twisting (internal/external rotation) of the leg.
- $\circ$  Your surgeon will determine the timeline for these restrictions.
- You will also have difficulties for dressing and need for mechanical aids.
- Physical therapy is an important part of the recovery process. The length of stay in the hospital for most of you will be about 1 to 3 days, during which time you will work with a physical therapist to develop exercises and follow a rehabilitation program.
- You may need physiotherapy up to 3 month depending on your condition.
- The rehabilitation program generally includes exercises to stretch and strengthen the muscles surrounding the hip joint, as well as training in activities of daily living, such as stair climbing, and walking.
- Most of you will be able to resume your activities of daily living within 3 to 6 months.
- Your ability to perform household, domestic tasks (for example cutting toenails, having a bath, climbing stairs) will improve.
- About 84 in 100 (84%) of you will be able to maintain your own home, 6 in 100 (6%) of you will live at home with assistance, and only 10 in 100 (10%) will need someone to take care of you fulltime 20 years after operation (Data from patients average age 80 years; range, 56-98 years).
- $\circ~$  You might be able to return to recreational sports after 6 months after discussion with your surgeon.

### Long-term Outlook:

1 2 3	
3 4 5 6 7	
7 8 9	
10 11 12	
12 13 14	
15 16 17	
18 19 20	
21 22 23	
24 25 26	
27 28 29	
30 31 32	
33 34 35	
$\begin{array}{c} 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\end{array}$	
39 40 41	
42 43 44	
45 46	
47 48 49	
50 51 52	
53 54 55	
56 57 58	
59 60	


- About 90 out of 100 (90%) of your hip replacement will last longer than 10 years.
- About 85 out of 100 (85%) of your hip replacements will last longer than 20 years.
- Over the course of 15 to 20 years, the artificial hip joint will loosen and you may need a second replacement.

### **<u>Risks and complications:</u>**

- 6 months post operation, about 30 in 100 (30%) of you will have at least one complication.
- While some complications can be a bit more serious, most can be treated successfully, such as blood clots.
- ➢ Urine retention: About 20 to 35 in 100(20-35%) of you will experience it.
  - You may urinate frequently; you may feel an urgent need to urinate but have little success when you get to the toilet; or you may feel you still have to go after you've finished urinating.
- Infections: About 1 in 100 (1%) of you will develop an infection after the operation.
- It may occur in the wound or deep around the artificial implants.
  Deep joint infection: 0.2 in 100(0.2%) in first 90 days.
  - You will experience fever or chills due to the infection, unusually swelling of the hip joint. The hip replacement will be removed, and you will be without a hip joint and receiving antibiotics for months.
- Risk of a complication will be higher if you have other diseases. For instance, 40-50 in 100 (40-50%) of you who have at least three other conditions, such as heart disease, urinary tract infection, or obesity will experience a complication.
- Death: 0.3 out of 100(0.3%) patients who undergo hip replacement surgery will die.
- Blood clots in the legs or pelvis: About 0.5 in 100 (0.5%) before hospital discharge.
  - The blood clot, due to immobilization, causes pain and swelling in the affected leg that typically gets better in about a month. About 17% to 50% of you will have persisting leg swelling, pain, vein swelling, and skin induration, for a longer period, up to 2 years.

- If you are older, overweight, have cancer, or have experienced blood *clots before, you will be more likely to get blood clots after surgery*.
- This clot can potentially lead to another complication, which is localized swelling in the leg due to clot and decreased flow of blood to the heart.
- Dislocation of the hip: About 1 in 100 (1%) of you will have dislocated the hip by first week, 3 in 100 (3%) by eighth week, and about 4 in 100(4%) at the first 6 months
  - You could experience sharp, pain that become worse if the joint has moved. These symptoms will last until the damaged tissue has been allowed to rest and heal completely, and will require use of painkillers. Your orthopedic surgeon will have to pull on the leg to reposition the hip within the socket under anesthesia.
- > Nerve damage: 1 to 3 in evey100 (1%-3%) of you.

- If there is nerve damage, you will have decreased feeling or loss of strength in the leg, foot or ankle area. Around 0.5% of the patients will have the nerve damage permanently.
- Different leg lengths: Less than 1 in 100(1%) of you will need another operation because one leg is longer than the other.
  - You might need another surgery because the difference length of your legs will cause severe post surgery problems such as walking difficulty, pain, or dislocation.





### **Introduction**

Hip arthroscopy is a surgical procedure that gives doctors a clear view of the inside of the hip joint. This helps them diagnose and treat joint problems. The surgeon will make small cuts around your hip and look inside using a tiny camera. Other medical instruments may also be used inside to fix your hip. Patients with Osteoarthritis and hip pain who do not respond to conservative treatment and have no evident cause on standard radiographs, might be candidates for a hip arthroscopy. Arthroscopy has also been used to diagnose and evaluate other diseases affecting the hip, such as Femoroacetabular Impingement, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Perthes Disease, Synovial Chondromatosis, and Ankylosing Spondylitis of the hip.

### **Procedure:**







- Hip arthroscopy is performed through small incisions (about 0.5 to 1cm in length each) using a camera to visualize the inside of the hip joint.
- The tiny camera splits the muscle fibers. When the camera is removed, the muscle fibers return to their normal position and alignment.
- Surgeons will be able to see the joint through the camera, identify the problem(s), and
  - Repair torn cartilage
  - Remove loose pieces of cartilage, bone or ligaments
  - $\circ$  Reshape the bones
- The operation typically takes 60-90 minutes.

### **Benefits:**


- Arthroscopy can potentially delay the need for Total Hip Replacement surgery in the future.
- Minimally invasive procedure: You will have very small incisions (0.5-1cm in length each, two to four in total) around the hip.
- Outpatient procedure: You usually go home the same day that you have surgery.
- Short rehabilitation period: On the first day after surgery, you will begin the rehabilitation process. This includes getting out of bed and walking. You may be able to bear some weight on the treated leg right away.

1	
2	
3	$\nabla \mathbf{V}_{i}$ (11) $\mathbf{L}_{i}$ , where $\mathbf{L}_{i}$ , $\mathbf{L}_$
4	You will have greater chance of going back to play competitive
5	sports and a high functional level compare to total hip
6	replacement surgery.
7	
8	Early return to sport: Most patients find they are back to full
9	activities 3-4 months following hip arthroscopy.
10	activities of 1 months following mp at the occupy:
11	Recovery:
12	
13	Management:
14	
15	• You may have some pain and discomfort following your surgery. You
16	will be given a prescription for pain medication which can be taken as
17	needed.
18	needed.
19	• You will need to leave the patches on your wound and keep it dry for
20	
20	24 hours.
22	
23	Rehabilitation:
23	• You can have protected weight bearing (weight bearing as
25	
26	tolerated with crutches) immediately following surgery.
20 27	• You will need to begin physiotherapy as early as 48 hours
28	after surgery with the guidance of your physiotherapist.
29	• The rehabilitation will involve exercises to improve range of
30 31	
32	motion of the hip as well as strengthening exercises.
33	$\circ$ Your physiotherapist will help you decide when and how to
34	
34 35	progress your exercises in the long run.
36	$\circ$ It is very important that you will use crutches for the first
37	
38	two weeks after surgery to help protect the repair and
39	improve gait mechanics following surgery
40	We are the emistance of the letter for a state of the
41	$\circ$ You may require assistance with driving for up to 6 weeks.
42	• Exercises like stationary bike are a part of the rehab and may
43	• • • • •
44	begin as soon as 48 hours after surgery.
45	• Sedentary work can be partially resumed in one to two weeks.
46	
47	Labor-intensive work may require 3 months.
48	$\circ$ You can resume full physical activity will resume up to 3 to 6
49	
50	months depending on your goals.
51	Possible Risks and complications:
52	<u>i ossibie nisks and complications.</u>
53	Hip arthroscopy appears to be safe. The overall complication rate with
54	hip arthroscopy was 4 in 100 (4.0%) of you with the vast majority of
55	
56	complications being non-life or limb threatening in nature. Here are rare
57	complications that can occur:
58	
59	
60	

- Neurologic traction injury: About 0.3 in 100(0.3%) of you will experience it.
  - This is the least severe form of nerve injury.. The actual structure of the nerve remains intact, but there is a transient interruption in the sensations being conducted through the injured nerve fiber. You could have decreased feeling or loss of strength in the skin on the lateral part of your leg and genital area, but there is usually a complete recovery.
- Intra-abdominal Fluid Extravasations: About 0.15 in 100(0.15%) of you will experience it.
  - During the procedure, when fluid is removed from the hip joint by the arthroscopy, some fluid may leak into the abdomen. You could experience the sense of increased abdominal pressure and discomfort that involves a measurable change in the circumference of your abdomen sometimes with swollen legs.
- Dislocation of the hip: About 0.03 in 100(0.03%) of you will experience it.
  - You could experience sharp, pain that become worse if the joint has moved. These symptoms will last until the damaged tissue has been allowed to rest and heal completely, and will require use of painkillers. Your orthopedic surgeon will have to pull on the leg to reposition the hip within the socket under anesthesia.
- Blood clots in the legs or pelvis: About 0.06 in 100 (0.06%) of you will experience it during the first 6 months.
  - The blood clot, due to immobilization, causes pain and swelling in the affected leg that typically gets better in about a month. About 17% to 50% of you will have persisting leg swelling, pain, vein swelling, and skin induration, for a longer period, up to 2 years.





# Arthroscopy for Hip Osteoarthritis (LONG)



### **Introduction**

Hip arthroscopy is a surgical procedure that gives doctors a clear view of the inside of the hip joint. This helps them diagnose and treat joint problems. The surgeon will make small cuts around your hip and look inside using a tiny camera. Other medical instruments may also be used inside to fix your hip. Patients with Osteoarthritis and hip pain who do not respond to conservative treatment and have no evident cause on standard radiographs, might be candidates for a hip arthroscopy. Arthroscopy has also been used to diagnose and evaluate other diseases affecting the hip, such as Femoroacetabular Impingement, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Perthes Disease, Synovial Chondromatosis, and Ankylosing Spondylitis of the hip.





### **Procedure:**

- The hip joint is made up of two major parts. The hip joint is a ball and socket joint that not only allows flexion and extension, but also rotation of the thigh and leg.
  - The hip **socket**, which is cup-shaped, sits in the pelvis.
  - The **ball** is the upper end of the thighbone (called the femoral head).
- If you would like to sleep during the surgery, the anesthetist will put you to sleep, so you will not be awake and therefore will have no memory of the procedure.
- $\succ$  Anesthesia:
  - There are two anesthesia options for this procedure, you can either have a general or a regional (spinal) anesthetic. Both options are safe and your pain will be managed with both.
  - General anesthesia: you will be 'asleep' (unconscious) for the procedure and not have any memory of the surgery.
  - Regional anesthesia: local anesthesia will be put in your lower back to make your body numb so you won't feel the procedure. Although you will still be awake and aware of the procedure the anesthesiologist can give you sedation medication to make you quite sleepy so you aren't anxious and mostly unaware of the procedure.
- After you receive anesthesia, your surgeon will put your leg in traction.

#### **BMJ Open**

2	
3	$\circ$ This means that your hip will be pulled away from the
4 5	socket enough for your surgeon to insert instruments, see
6	the entire joint, and perform the treatments needed.
7	
8	$\circ$ The bones of the hip joint (the ball and socket) are
9	separated by approximately 1cm by applying traction to the
10	foot while wearing a special boot.
11 12	
13	Initially, air and/or fluid are injected into the hip, under x-ray
14	guidance. Once correct placement of the instrument has been
15	confirmed typically small incisions are made around the hip.
16	
17	Each of these incisions generally are approximately 0.5 to 1 cm in
18	length.
19	> Through these small holes, the tiny camera ('arthroscope') and
20	instruments are passed into the joint under x-ray guidance.
21 22	instruments are passed into the joint under x-ray guidance.
23	> The tiny camera will split the muscle fibers. When the camera is
24	removed, the muscle fibers return to their normal position and
25	alignment.
26	
27	Surgeons will be able to see the joint through the camera and
28	identify the problems. Depending on the problem encountered,
29	your surgeon will perform the appropriate procedures such as:
30 31	• Repair torn cartilage
32	-
33	<ul> <li>Remove loose pieces cartilage, bone or ligaments</li> </ul>
34 35	• Reshape the bones
36	The operation typically takes 60-90 minutes but duration will
37	
38	vary depending on the problem in the hip joint but can last up to
39	120 minutes.
40	> After surgery, you will stay in the recovery room for 1 to 2 hours,
41 42	then stay in the surgery area before being discharged to go home.
43	then stay in the surgery area before being discharged to go nome.
44	
45	Derective
46	Benefits:
47	Arthroscopy can potentially delay the need for Total Hip
48	Replacement surgery in the future.
49	
50 51	Main possible benefits of arthroscopy compared to total hip
52	arthroplasty:
53	<ul> <li>Relief of symptoms, including reduced pain.</li> </ul>
54	• Functional improvement, meaning increased mobility and
55	regained ability to perform activities of daily living, the
56	regarded assing to perform denvines of daily fiving, the
57	

BMJ Open
<ul> <li>extent of which depend on the severity of your OA and other pre-existing conditions before the surgery.</li> <li>It helps to diagnose and treat early causes of arthritis, possibly preventing progression.</li> <li>Hip arthroscopy is a minimal invasive surgery compared to the open surgical alternatives. You will have very small incisions (about 0.5-1 cm each in length, two to four in total) around the hip, leading to minimal scarring.</li> <li>Outpatient procedure: You usually go home the same day or the next day that you have surgery.</li> </ul>
• You will have chance of going back to activity at a high functional level. For example, playing competitive sports such as soccer or hockey.
Less restriction on physical activities than after a hip replacement: On the day after surgery, you will begin the rehabilitation process. This includes getting out of bed and walking.
You can bear some weight on the treated leg the day after surgery.
• You will be able to ride the stationary bike 48 hours after your surgery.
Early return to physical exercise: Most likely you will go back to full activities 3 to 6 months following hip arthroscopy.
<ul> <li>One to two weeks after the surgery after your wound has healed, you can walk in the pool.</li> </ul>
<ul> <li>Approximately six to eight weeks after the surgery, you maybe able to increase activities including light aerobic exercise.</li> <li>Approximately 3-6 months after surgery, you will be able to do unrestricted exercise and recreational sports after discussion with your surgeon.</li> </ul>
• These sports may include soccer, football, tennis, etc.
Recovery:
Management:
$\circ~$ After hip arthroscopy your wound is covered with patches.
<ul> <li>You will need to leave the patches in place and to keep your wounds dry for 24 hours.</li> </ul>
<ul> <li>You will be given a prescription for pain medication following your surgery which you will take as needed.</li> </ul>

	• You will be given oral or intravenous antibiotics to prevent infection and you may also be given a medication to prevent blood clots in the legs.
$\triangleright$	Rehabilitation:
0	You are able to have protected weight bearing (weight bearing as tolerated with crutches) immediately following surgery.
0	You will need to begin physiotherapy as early as 48 hours after surgery.
0	Exercises like stationary bike are a part of the rehab and may begin as soon as 48 hours after surgery.
0	Your physiotherapist will guide you through the rehabilitation program, which will involve exercises to improve range of motion of the hip as well as strengthening exercises.
0	Your physiotherapist will help you decide when and how to progress your exercises in the long run.
0	It is very important that you use crutches for the first two weeks after surgery to help protect the repair and improve gait mechanics following surgery. The rehabilitation progress, as well as the extent of the tear and/or associated problems, will determine the weaning process.
0	Your joint can be quite sore at first, and it may need some time to settle. Therefore, you are not allowed to do movements/activities that may provoke the pain such as lifting, twisting, overstretching, and jarring.
0	You may require assistance with driving for up to 6 weeks.
0	In most occupations, such as sedentary job, you will be able to return to work in one to two weeks. However, since the return at this point will not be completely normal you may need some breaks in between. You may not be able to work they whole day, but you can be productive.
0	If your job requires significant manual labor and lifting, the return may not occur completely until at least three months following surgery. A discussion with your surgeon may be needed too.
0	Full physical activity will resume up to 3 to 6 months depending on your goals.
Risks	s and complications:

Hip arthroscopy appears to be safe. Although about 4 in 100 (4%) of you may present some kind of complication, most of the complications are not life or limb threatening.

- Neurologic traction injury: About 0.3 in 100 (0.3%) of you will experience neurologic traction injury
  - This is the least severe form of nerve injury. The actual structure of the nerve remains intact, but there is a transient interruption in the sensations being conducted through the injured nerve fiber. You could have decreased feeling or loss of strength in the skin on the lateral part of your leg and genital area, but there is usually a complete recovery.
  - Most commonly, numbress will go away within a week or so. In some cases, smaller areas may continue to be numb for several weeks.
- Intra-abdominal fluid collections: About 0.15 in 100 (0.15%) of you will experience fluid collections
  - During the procedure, when fluid is removed from the hip joint by the arthroscopy, some fluid may leak into the abdomen. You could experience the sense of increased abdominal pressure and discomfort that involves a measurable change in the circumference of your abdomen sometimes with swollen legs.
- Dislocation of the hip: About 0.03 in 100 (0.03%) of you will experience dislocation during the first 6 months
  - You could experience sharp, pain that become worse if the joint has moved. These symptoms will last until the damaged tissue has been allowed to rest and heal completely, and will require use of painkillers. Your orthopedic surgeon will have to pull on the leg to reposition the hip within the socket under anesthesia.
- Blood clots in the legs or pelvis: About 0.06 in 100 (0.06%) of you will experience blood clot during the first 6 months.
  - The blood clot, due to immobilization, causes pain and swelling in the affected leg that typically gets better in about a month. About 17% to 50% of you will have persisting leg swelling, pain, vein swelling, and skin induration, for a longer period, up to 2 years.

# **BMJ Open**

#### Patients' values and preferences of the expected efficacy of hip arthroscopy for osteoarthritis: A protocol for a multinational structured interview-based study combined with a randomized survey on the optimal amount of information to elicit preferences

Journal:	BMJ Open
Manuscript ID:	bmjopen-2014-005536.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Aug-2014
Complete List of Authors:	Zhang, Yuqing; McMaster University, Clinicial Epidemiology and Biostatistics Tikkinen, Kari; Helsinki University Central Hospital and Clinical Research Institute HUCH Ltd., Department of Urology Agoritsas, Thomas; McMaster University, Department of Clinical Epidemiology and Biostatistics Ayeni, Olufemi; McMaster University, Department of Surgery Alexander, Paul; McMaster University, Department of Clinical Epidemiology and Biostatistics Imam, Maha; University of Waterloo, Pharmacy Yoo, Daniel; McMaster University, Faculty of Health Sciences Tsalatsanis, Athanasios; University of South Florida, Division of Evidence- based Medicine Djulbegovic, Benjamin; University of South Florida, Center for Evidencebased Medicine and Health Thabane, Lehana; McMaster University, Department of Clinical Epidemiology & Biostatistics Sch nemann, Holger; McMaster University, Dept. of Clin. Epidemiology and Biostatistics Guyatt, Gordon; Mcmaster University, Clinical Epidemiology and Biostatistics
<b>Primary Subject Heading</b> :	Surgery
Secondary Subject Heading:	Surgery, Evidence based practice, Communication, Sports and exercise medicine
Keywords:	Patients' values and preference, Total Hip Arthroplasty, Orthopaedic & trauma surgery < SURGERY, Hip Arthroscopy, Patient Written Information, Decision Making

SCHOLARONE<sup>™</sup> Manuscripts

1 2 3 4	Patients' values and preferences of the expected efficacy of hip arthroscopy for osteoarthritis: A protocol for a multinational structured interview-based study combined with a randomized survey on the optimal amount of information to elicit preferences
5 6 7 8 9	Yuqing Zhang, Kari A.O. Tikkinen, Thomas Agoritsas, Olufemi R. Ayeni, Paul Alexander, Maha Imam, Daniel Yoo, Athanasios Tsalatsanis, Benjamin Djulbegovic, Lehana Thabane, Holger Schünemann, Gordon H. Guyatt.
10 11 12 13	Yuqing Zhang, doctoral candidate, Department of Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main St., Hamilton, ON, Canada, L8S 4K1, e-mail Madisonz1220@gmail.com.
14 15 16 17	Kari A.O. Tikkinen, <i>post-doctoral fellow</i> , Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; and Department of Urology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
18 19	Thomas Agoritsas, <i>research fellow</i> , Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
20 21	Olufemi R. Ayeni, <i>consultant orthopaedic surgeon</i> , Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, ON, Canada.
22 23 24	Paul Alexander is doctoral candidate, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
24 25 26 27 28	Maha Imam, student, Faculty of Pharmacy, University of Waterloo, Kitchener ON Daniel Yoo, student, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. Athanasios Tsalatsanis, <i>assistant professor</i> , Division of Evidence-based Medicine, University of South Florida,
29 30 31 32 33	<ul> <li>Tampa, FL, USA.</li> <li>Benjamin Djulbegovic, <i>distinguished professor</i>, Department of Internal Medicine, University of South Florida; and</li> <li>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.</li> <li>Lehana Thabane, <i>Professor/Associate Chair</i>, Department of Clinical Epidemiology &amp; Biostatistics, McMaster</li> <li>University, Hamilton, ON, Canada.</li> </ul>
33 34 35 36 37 38	Holger Schünemann, <i>Professor and Chair</i> , Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada.
39 40 41	Gordon H. Guyatt, <i>distinguished professor</i> , Department of Clinical Epidemiology and Biostatistics, and Medicine, McMaster University, Hamilton, ON, Canada.
42 43 44 45 46	<i>Correspondence to:</i> Gordon H. Guyatt, Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, guyatt@mcmaster.ca. Tel: (905)525-9140 x 22900FAX: (905)524-3841
47 48 49 50	<i>Keywords</i> Patients' values and preference, Total Hip Arthroplasty, Hip Arthroscopy, Osteoarthritis, Patient Written Information, Decision Making, Uncertainty
51 52 53 54 55 56	Word count: 5003
57 58 59 60	1

# Abstract:

INTRODUCTION: Symptomatic hip osteoarthritis (OA) is a disabling condition with up to 25% cumulative lifetime risk. Total hip arthroplasty (THA) is effective in relieving patient's symptoms and improving function. It is, however, associated with substantial risk of complications, pain and major functional limitation before patients can return to full function. In contrast, hip arthroscopy (HA) is less invasive, and can postpone THA. However, there is no evidence regarding the delay in the need for THA that patients would find acceptable to undergo HA. Knowing patients' values and preferences (VP) on this expected delay is critical when making recommendations regarding the advisability of HA. Furthermore, little is known on the optimal amount of information regarding interventions and outcomes needed to present in order to optimally elicit patients' VP. 

METHODS AND ANALYSIS: We will perform a multinational, structured interview-based survey of preference in delay time for THA among patients with non-advanced OA who failed to respond to conservative therapy. We will combine these interviews with a randomized trial addressing the optimal amount of information regarding interventions and outcomes required to elicit preferences. Eligible patients will be randomly assigned (1:1) to either a short or a long format of health scenarios of THA and HA. We will determine each patient's VP using trade-off and anticipated regret exercises. Our primary outcomes for the combined surveys will be: 1) the minimal delay time in the need for THA surgery that patients would find acceptable to undertake HA, 2) patients satisfaction with the amount of information provided in the health scenarios used to elicit their VPs. 

ETHICS AND DISSEMINATION: The protocol has been approved by Hamilton
 Integrated Research Ethics Board (HIREB13-506). We will disseminate our study
 findings through peer-reviewed publications and conference presentations, and make
 them available to guideline makers issuing recommendations addressing HA and
 THA.

# BACKGROUND

6 7

8

9

10

11

# **Osteoarthritis and surgical options**

Osteoarthritis: Osteoarthritis (OA) is the most common form of chronic arthritis. Approximately 15% of men and women suffer from symptomatic OA[1], representing a large burden on patients, the healthcare system and society. Symptomatic hip OA is a particularly disabling condition with a 12 cumulative lifetime risk of up to 25%. Conservative management of hip OA includes exercise, 13 weight reduction, physical therapy and medications focusing on relieving symptoms, improving 14 joint function, and optimizing quality of life[2]. Pharmacological and non-pharmacological 15 interventions for severe OA are, however, substantially less effective than surgical treatment[3]. 16 17 Consequently, most patients with severe hip OA eventually need total hip arthroplasty (THA)[3]. 18

19 Total hip arthroplasty: With an aging population increasingly interested in staying physically active 20 [4], the frequency and cost of THA continues to grow. Currently more than a half million THA 21 22 procedures are performed annually in the UK and USA alone, and in 2010 the global market was 23 estimated as high as 4.7 billion USD[5]. 24

25 After failure of conservative treatment, THA is usually effective in relieving patient's symptoms 26 27 and improving function, with more than 95% prosthesis survivorship at 10-year follow-up and more 28 than 80% survivorship at 25-year follow-up[6, 7]. However, THA is also a major procedure, 29 associated with substantial risk of complications, and with weeks of pain and major functional 30 limitations before patients can return to full function. Therefore, patients and caregivers are 31 32 interested in less invasive interventions that could postpone THA. 33

34 Hip arthroscopy: Less invasive interventions include arthroscopy, partial replacements, and bone-35 preserving techniques. They have shown varying success rates among OA patients[8]. Hip 36 37 arthroscopy (HA) is a new and the fastest growing procedure within orthopedic surgery[8]. Despite 38 the lack of high quality evidence, the number of HAs performed is expected to double in the United 39 States in 2013 compared to 2011[9]. HA is used to treat intra articular pathology of the hip, 40 including mild hip OA. Compared to THA it has the advantages of being minimally invasive and 41 42 having fewer complications [10]. Compared to THA, arthroscopy may help patients achieve higher 43 level of function more quickly with, over the short term less restriction on exercise. The expectation, 44 however, is that patients' underlying osteoarthritis will progress, and THA will ultimately become 45 necessary. The question then arises: what delay in the need for THA would warrant a patient 46 47 undergoing HA? This is a question of values and preferences.

#### 48 49

#### Measuring patients' values and preference 50

51 52 There are a number of techniques available for eliciting patients direct choices of which the 53 probabilistic version of the Threshold Technique (TT) also called probability trade-off (PTO) 54 exercise is widely used [11]. Following descriptive and probabilistic information regarding benefits 55 and harms associated with treatment choices - for example treatment A and B - in which the 56 relative benefits of treatment A versus B are large, the respondent is asked to choose one option. 57 58 Typically, patients will choose treatment A. The interviewer then presents an alternative situation 59 in which the relative benefits of A versus B are very small, and patients typically choose B. The 60

Page 5 of 71

### BMJ Open

interviewer than presents a small reduction in the probability of benefits, relative to the first scenario, for option A. If the patient continues to choose A, the next scenario presents a small increase in the benefits of A versus B relative to the second scenario. The process is repeated until

 $\frac{3}{4}$  the indifference point between A and B is established (ping pong approach)[12].

5 6

1 2

Utility elicitation uses a very different approach, presenting health states and using one of a
variety of techniques to elicit the respondent's rating of the value of the health state on a scale
between death (typically 0) and full health (typically 1.0 or 100). The patients' responses are used to
build a decision model that calculates the treatment option that, given the patient's utilities,
achieves the maximum utility-adjusted outcome [13, 14].

14 Complementary approaches to assess patients' decision-making integrate emotional aspects of the 15 process. One such approach focuses on regret, an aversive emotion people experience when they 16 believe their current situation would have been better had they acted differently in the past[15, 16]. 17 In theory, regret is influenced by both intuitive, affect-based, and analytical, deliberative 18 19 processes[17, 18]. Reflecting on the anticipated regret of particular decisions (e.g. choosing A versus 20 B in the example above) may alert people to the choice that would be most likely to avoid this 21 aversive emotion[19, 20]. The anticipated regret theory-based approach preserves a rational 22 23 decision-making framework, while allowing anticipation of the effect of the decision on 24 emotions[21]. 25

Using both (direct choice) trade-off and anticipated regret exercises, our study will provide
 empirical evidence regarding the delay in the need for THA that patient would find acceptable to
 undergo HA.

# Amount of information presented to elicit patients' values and preference 33

34 The choices patients make are critically dependent on how the health scenario (HS) that 35 characterizes the processes and outcomes of the alternative management options (A and B in the 36 above – THA and HA in the current project) are presented. Research in marketing has addressed 37 some of the relevant issues. Information-processing framework[22] suggests that that there are 38 39 limits to the human ability to assimilate and process information, and that once these limits are 40 surpassed behavior becomes confused and dysfunctional[23]. Evidence suggests an inverted U-41 shaped relationship between information available and decision quality, in which individuals with 42 too little or too much information made poorer decisions than those with an intermediate amount of 43 44 information [24, 25]. 45

Other indirect evidence comes from research on written consent forms [26, 27]. Individuals often
 skim over consent forms for clinical trials in oncology if they are longer than 1,000 words or 4
 pages[28]. Twenty-seven oncology trials showed that patients obtain significantly higher objective
 knowledge when the consent form page count was seven or less [29].

52

In the area of pharmaceutical product choice, participants have had better understanding of shorter
 and easier information presentations[25]. One might expect, however, that if the information
 becomes too scanty, decision quality will deteriorate.

# 57 58 Patients' values and preferences on osteoarthritis surgical options

 $_{60}^{59}$  Given the existing evidence, both HA and THA represent reasonable choices for patients with non-

advanced OA. The choice may, however, be challenging. On one hand, HA is likely to achieve only transient improvement in function. On the other hand, the morbidity associated with THA is substantial.

Therefore, one of the key aspects in the choice between HA and THA is the duration of delay in the need for THA that patients may achieve with HA. If patients demand a delay time much greater than HA can realistically achieve, the procedure should seldom be considered. On the other hand, if patients would be satisfied with much shorter delay time, the procedure should be frequently considered. There is currently no empirical evidence addressing patients' values and preferences 10 regarding the delay they would demand to undertake HA. Knowing typical patients' values and 11 preferences regarding this expected delay is likely to be helpful for patients and health care 12 13 providers in the clinical encounter and for guideline panelists when making recommendations 14 regarding the advisability of HA. 15

The assessment of patients' values and preferences will be valid only to the extent patients receive sufficient accurate information on the outcomes of available treatment options presented in ways 18 that they can easily process. Thus far, only limited indirect evidence informs us on the optimal amount of information to provide in scenarios when eliciting patients' preferences.

Our study will provide direct empirical evidence on the optimal amount of information to provide when eliciting patients' values and preferences. It may also provide insight into the amount of information to provide in shared-decision making, although our study only indirectly addresses that issue.

#### 28 **OBJECTIVES** 30

1 2

3

4 5 6

7

8

9

16

17

19

20

21 22

23 24

25

26

27

29

37

41

47

49

53

54 55 56

31 General Objective: The purpose of this study is to improve the management of patients with non-32 advanced symptomatic hip osteoarthritis (OA) who failed conservative treatment by determining 33 their values and preferences regarding the choice between immediate total hip arthroplasty (THA) 34 35 versus hip arthroscopy (HA). 36

In the **Pilot stage** of our study, we will assess the following feasibility issues: (i) recruitment rate; 38 39 (ii) length of time to conduct the interview and fill out all the study measurements; (iii) potential 40 personnel and data management issues.

42 In **Study 1** – our primary objective is to determine the minimal delay time in the need for THA 43 surgery that patients would find acceptable to undertake HA (which we will refer to as the "delay" 44 45 time"). Secondary objectives include assessing patients' anticipated regret if the delay would differ 46 from their expectations, as well as potential determinants of their preference (e.g., age, gender, educational level, and socioeconomic status). 48

50 In **Study 2** – our objective is to assess the ease of understanding, optimal quantity of information, 51 and patients' satisfaction regarding alternative formats of the HSs used to elicit their preferences. 52

# **METHODS**

#### 57 Study design 58

9

10

### BMJ Open

## Pilot study

- In a pilot study, we will assess the following feasibility issues: (i) recruitment rate; (ii) length of
- <sup>3</sup> time to conduct the interview and fill out all the study measurements; (iii) potential personnel and
- data management problems in real-life setting. We will perform this study at the outpatient
   orthopedic clinic of the McMaster University Medical Center (Hamilton, ON, Canada).
  - Study 1: We will perform a multinational, cross-sectional, structured interview-based survey to assess the delay in THA that patients would demand to choose HA.
- Study 2: Within Study 1, we will conduct a randomized trial comparing a short version versus a
   long version of HA and THA health scenarios.
- <sup>14</sup> Table 1 shows the study flow.

Setting: The study will take place at McMaster University Medical Center, Hamilton, Canada; St.
 Michael's Hospital, Toronto, Canada; Hospital de Sant Pau, Barcelona, Spain; and Sorocaba
 Hospitals, São Paulo, Brazil.

# Study population

The population of interest consists of adults diagnosed with non-advanced hip OA. Table 2 presents
 the detailed inclusion and exclusion criteria.

# 2627 Recruitment strategy

We will prospectively identify consecutive patients confirmed with non-advanced hip OA referred for consideration of HA. The orthopedic surgeon will send a letter in advance of their visit to inform patients about our research project and the possibility of being approached by our research assistant (RA) for this study. The RA will then make initial contact with all the patients by phone to explain the purpose of the study. When the patients come to the orthopedic clinic, we will ask patients for their written informed consent.

# <sup>36</sup> <sup>37</sup> Participants interview

38

#### 39 Baseline information 40

We will document patients' age, gender, ethnicity, educational level (not completed high school;
completed high school only; some college/university; completed college or university), yearly income,
and their impression of the experience of close relatives or friends who have undergone HA or THA
(categorized as extremely dissatisfied; dissatisfied; neutral; satisfied; extremely satisfied, or
differing across individuals).

4849 Health scenarios

50

The health scenarios are designed to inform patients of the surgical options. Based on available evidence [30] we will include the following five sections in the HSs for THA and HA: [26] Brief introduction to the surgery; [31] Description of the surgical procedure; [iii] Post-operative recovery and rehabilitation; [32] Expected benefits; [v] Risks and potential complications. *(See appendix: Script #1: Health scenarios)* 

58

59 The short versions have approximately 850 words and the long versions approximately twice the 60

number of words; both versions use the same sub-headings.

To ensure we present accurate estimates of benefits and risks of THA and HA to patients[33], conveyed in the most simple and easy-to-understand way possible, we applied a rigorous process to develop these health scenarios.

Firstly, we performed a search on PubMed to retrieve relevant content from systematic reviews, randomized control trials (RCT), and observational studies. Evidence from systematic reviews was preferred if available.

Secondly, we reviewed THA booklets from Brant Community Healthcare System, Hamilton Health
 Sciences, Joseph Brant Memorial Hospital, Niagara Health System, St. Joseph's Healthcare
 Hamilton, National Institute of Arthritis and Musculoskeletal, and Skin Diseases (NIAMS) to
 inform SCENARIO design and content. For both THA and HA, we also reviewed information from
 other sources such as the Informed Medical Decisions Foundations (IMDF) [34] and National
 Institute of Health for both THA and HA HSs (when available).

21 22 Thirdly, we considered the following strategies to increase the ease of understanding and 23 readability of our scenarios[35]. We focused the material on key concepts with consistent and 24 simple words aiming for 1-2 syllables[32, 36]. A clear topic sentence are used at the beginning of 25 26 each sub-heading with following details and examples[37]. We used conversational style with the 27 second person point of view (i.e., "you")[37]. We also used the Flesch-Kincaid Grade Level test in 28 Microsoft Word 2011 to ensure the English is understandable for people with grade 10 level 29 education. 30 31

Finally, we revised our scenarios based on feedback from 15 orthopedic surgeons (8 of them commented on THA, and 7 of them commented on HA); from 2 focus group (3 patients in each group) and 4 individual interviews with a total of 10 patients (5 for each surgery) who had undergone THA or HA; and 5 physiotherapists.

For the Spanish and Portuguese part of the study, an experienced medical translator will
undertake the initial translation. In each language, one clinical epidemiologist and one orthopedic
surgeon, native in the non-English language and fluent in English, will check the translation and
discuss potential revisions with the translator. After we obtain the Spanish and Portuguese
versions, back translations will be performed and checked by the epidemiologist and the orthopedic
surgeon, with further revisions to the Spanish and Portuguese versions if necessary.

46 47

1 2

3

4

5 6

7 8

9

10

19 20

<sup>47</sup><sub>48</sub> Randomization of the health scenarios

Participants will be randomized to receive the short format or long formats of the scenarios in coded
 packages that the interviewer will open at the start of the interview. We will use central
 randomization at McMaster University using an allocation ratio of 1:1 with random blocks size
 (2,4,8).

We will ask participants to read hard copies of the corresponding health scenarios (short or long).
At the end of the interview – i.e., after the trade-off exercise, anticipated regret exercise, and a
check for consistency and understanding that we will describe subsequently – the RA will show

3

4 5 6

7

#### **BMJ Open**

patients in each group the version they have not yet seen and ask about their preferred format. If participants have more content questions regarding the scenarios, the RA will instruct the patient

to ask the orthopedic surgeon for further assistance in the patient-doctor consultation after the interview.

## Trade off exercise

8 After participants have read the initial health scenario (short or long version), we will assess the 9 minimum acceptable delay (delay time) in THA that patients would find acceptable to undergo HA. 10 We will use the following generic questions: "By how much longer should the arthroscopy postpone 11 the need for hip replacement surgery for you to consider the hip arthroscopy worthwhile? Would 12 you choose hip arthroscopy if it would delay the need for total hip replacement by [delay time in 13 14 months/year]?" We will offer a range of delay times, alternating between short and long times in a 15 ping-pong strategy, e.g.: 3 months – 12 years – 6 months – 10 years, etc. We will progressively 16 narrow the range of the alternatives offered as we repeat the exercise. 17

#### 18 19 20

The lower bound of delay time offered (i.e. 3 months) is just below the anticipated least stringent 21 participants' demand and also corresponds to the shortest follow-up time in studies that evaluate 22 23 the efficacy of HA[38]. For the upper bound initially offered, the literature suggests that the most 24 optimistic estimate of the time which HA may delay THA is approximately 10 years[39]. If patients 25 are not satisfied with the upper boundary of the delay time – that is, they would demand a delay of 26 more than 12 years before they would undergo HA – there will be provision for them to express this 27 preference. 28 29

#### 30 Anticipated regret exercise 31

32 Following the trade-off exercise, we will assess participants' anticipated regret associated with 33 choosing or not choosing a treatment alternative. We will measure anticipated regret using a 100 34 35 mm visual analog scale (VAS) called the Feeling Thermometer (FT)[40], anchored at no regret (0) to 36 maximum regret (100). (Figure 1 anticipated regret VAS) 37

38 We will assess anticipated regret at five different time points (the patient personal threshold 39 determined during trade-off exercise, as well as two shorter and two longer options). For example, if 40 41 the patient chose 2 years as their shortest delay time, we will ask her: "How much regret would you 42 feel about choosing hip arthroscopy if you need to have a total hip replacement surgery after 12 43 months / 1.5 years / 2 years / 3 years / 4 years?. This process allows us to check for inconsistent 44 answers (see below). 45 46

#### 47 Blinding 48

Since this is a patient educational trial, the interviewers (data collectors) cannot be blinded. The 49 orthopaedic surgeons, patients (outcome assessors), and data analysts will be blinded to sequence of 50 51 giving HSs. 52

## **Outcomes**

53 54

55 56 57

58

60

Our primary outcome measures for the pilot stage regarding feasibility issues are the recruitment rate, length of time to conduct the interview and fill out all the outcome measurements. We will 59

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

explore the potential personnel and data management problems in the McMaster Medical center to ensure the quality of the definitive stage of our study. We will note the number of participants enrolled each week. The mean and standard error of the center's recruitment rate over recruitment period will be our study recruitment rate. We will also calculate the percentage of eligible patients who agree to participate. We will time the length of the interview, the length of finishing interviewers' administrated or patients' administrated questions.

We will consider recruitment feasible for a large study if we will be able to recruit two patients at McMaster Medical center per week (i.e., 100 subjects over 50 weeks). We will consider the pilot 10 stage (approximately 2 months) to be successful, and a large multicenter RCT to be feasible if: (i) we 11 successfully recruit 20% of the patients according to our estimated sample size in 2 months; (ii) we 12 13 will be able to finish the interview and all the outcome assessment in approximately one hour. (See 14 table 3 for outcomes and corresponding objectives) 15

16 We will modify our protocols in response to limitations with respect to excessive length of the interview, difficulties with comprehension or ambiguities in the questions, and personnel or data 18 management problems identified in the pilot.

For Study 1, our outcomes are:

Primary outcome: the minimal delay in the need for THA surgery that patients would find acceptable to undertake HA (which we will refer to as the "delay time").

Secondary outcomes:

1 2

3

4

5 6

7 8

9

17

19

20 21

22 23

24 25

26 27

28 29

30

31 32

33

34 35

36

- (i) Independent predictors of the primary outcome include age, gender, educational level, socioeconomic status, and family/friends' experiences with previous THA or/and HA.
- Patients' anticipated regret scores on a 100mm VAS at five different time points (the one (ii) patients chose in the trade-off exercise, and two shorter and two longer options).

For Study 2 our outcomes are:

37 Primary outcome: patients' satisfaction on the scenarios after reading the initial scenarios. 38 39 Interviewers will determine the degree of satisfaction participants place in the scenarios using a 7-40 point Likert-type scale with response options: completely dissatisfied, mostly dissatisfied, 41 somewhat dissatisfied, neither satisfied nor dissatisfied, somewhat satisfied, mostly satisfied, 42 completely satisfied. 43

44 Secondary outcomes:

- 45 1. Ease of understanding: we will assess participants impression of each of understanding of 46 each scenario using a 7-point Likert-type scale with response options: extremely hard, very 47 hard, hard, not easy not hard, easy, very easy, extremely easy. 48
- 49 2. Information quantity: we will ask participants to rate the quantity of the information 50 displayed in the initial presented scenario by a 7-point Likert-type scale with response 51 options: much too little, somewhat too little, slightly too little, about right amount of 52 53 information, slightly too much, somewhat too much, much too much.
- 54 3. Patients' preference on length of format: After patients finish reading both the long and short 55 versions of scenarios we will ask them about their preference for the short or long version, 56 using a 7-point Likert-type scale with response options: short version much better, short 57 version somewhat better, short version little better, no preference, long version little better, 58 59 long version somewhat better, long version much better. 60

6

# **Data collection**

A trained interviewer will collect all the outcomes by completing the case-report forms (CRFs) at the end of the interview. No follow-up and further data collection will be involved.

# Sample size calculation

Study 1:

Due to the paucity of similar studies in literature, we are unable to estimate the standard error (SE) of delay time precisely. If the data is normally distributed, 99.7% of the area under of the normal distribution curve lies within 3 standard deviations[41]. We assume the range of delay time (12 years) will be normally distributed. Therefore, we anticipate a SD of approximately 2 years. We developed the sample size estimation table using the SD and varying the confidence interval around the mean to obtain sample size using the formula below[42] (Table 4). 

 $n = \frac{4z_{1-\frac{\alpha}{2}}^2\sigma^2}{I^2}$ 

N represents the sample size,  $\sigma$  represents the SE, L represents the confidence interval around the mean. 

At the end of the pilot stage we will calculate the SE of delay time in the 20 patients as a reference point to modify our earlier sample size estimation for the definite study.

Study 2:

Based on Cohen's rule of sums [43], we used "SD=0.5" to calculate the sample size to achieve a medium effect size. With a sample size of 62 in each group the trial is powered to detect a medium effect size of mean = 0.5 or larger given 80% power level and  $\alpha$  = 0.05 in a two-sided test. Considering the result will be obtained immediately after the assessment and all outcomes will be interviewer administrated, we anticipate no loss to follow-up. We also made a sample size estimation table with different confidence intervals around the mean (Table 4). Sample size calculation is performed using SPSS (Statistical Package for the Social Sciences) version 21.0 for Windows. 

After finishing the pilot stage of our study, we will compare the estimated sample size for study 1 and 2 and take the larger number as our final sample size for the combined studies. 

#### Data analysis and interpretation

Study 1 

Description of baseline characteristics:

We will present patients' age, gender, ethnical / cultural group, educational level, socioeconomic status and medical history[44]. Means and standard deviations (SD) will be used to present continuous variables and two-tailed T-test (or Mann-Whithey U test for non-normal distributions) to detect significant differences (p<0.05) between group means. We will use proportions and

frequency tables to present categorical variables and a two-tailed Fisher's Exact test will be used to detect statistically significant (p<0.05) differences between two groups.

### Primary and secondary outcome(s):

We will assess the distribution of the mean delay time and represent it graphically using histogram(s). If the data is normally distributed we will present the mean delay time and SD. We will also estimate 95% confidence intervals of the mean respectively. If the data is skewed, we will present the mode, median, and interquartile range.

Multiple variable linear regressions will be undertaken to determine statistically independent predictors of the threshold of delay time. In this analysis, the delay time will be the dependent variable and the independent variables will be the previous experience of THA and HA in friends and family, age, gender, socioeconomic status, educational level.

After presenting the health scenarios and recording participants' response with both "trade off" and anticipated regret exercise, we will compare results between these two measurements of participants' values and preferences.

We have defined three possible patterns of inconsistent response (See table 5 Inconsistency checking). If the participants' answers fall into any of these patterns, interviewers will review participants' original answers without, however, implying that they must modify their original choices. If the participants confirm their original answers, interviewers will determine and record the reasons of participants' inconsistent choices based on participants' explanation. If patients, following review of the relation between their trade off and regret choices, desire to modify their chosen delay time, interviewers will repeat the trade-off exercise.

For the analyses above, we will determine whether the delay time differs between those with an apparently high level of understanding and those who demonstrate any of the inconsistencies depicted in Table 2. If we find an important discrepancy between the results of patients categorized as understanding and not understanding, we will focus our primary analysis on the group of patients who apparently have a high level of understanding.

Study 2

<sup>3</sup> Baseline characteristics description

We will summarize patients' age, gender, ethnical / cultural group, educational level, social economics status in a table.

<sup>48</sup> Primary and secondary outcome(s): <sup>49</sup>

Our primary outcome will be participants' satisfaction of the health scenarios assessed by a 7-point Likert scale. We will also visualize it by using histogram(s). We will conduct a two-sided student Ttest will to compare mean satisfaction scores and ease of understanding between the short and long scenarios. We will also calculate the mean difference and 95% confidence intervals.

For information quantity, we will present a histogram depicting the proportion of participants'
 choice in each category. We will apply 2 approaches to analyze information quantity at the first
 assessment. First, we will determine if the distribution between two groups differ by greater than

3

4

**BMJ Open** 

chance with two-sided student T-test (if its normally distributed) or Mann-Whitney U test(if its not normally distributed). Second, using a chi-square test we will determine if the proportions of participants who choose "about the right amount of information", in comparison to those who choose other response options, differ between groups.

We will use 2 approaches to compare participants' preferences for the short versus long formats after showing patients both scenarios. First, we will treat the outcomes on the 7-point scale as multinomial ordered outcomes. We will analyze the result using Mann-Whithey U test. Second, we will use a more conservative approach and compare the proportions of participants who prefer the short format to the proportion of participants who have either no preference or prefer the long format by using a chi-square test. (Table 3: Summary of analysis plan).

# <sup>14</sup><sub>15</sub> ETHICAL AND DISSEMINATION

This study will be performed in accordance with established guidelines for research involving 16 17 human patients. The proposed study does not pose any safety risks to participating patients. The 18 protocol has received Research Ethics Board approval at Hamilton Health Sciences (McMaster 19 University Medical Centre) and will be submitted for approval at the other participating sites. The 20 research objectives and study intervention will be explained to the patient verbally and in writing 21 22 in easily comprehensible language. Written informed consent will be obtained from all patients. 23 Patients will be informed of their right to ask for further information at any time and to withdraw 24 from study without prejudice to their future care. In the unlikely event that participants find 25 considering the above scenarios upsetting, the interview will be immediately stopped and support 26 27 offered. We will ensure confidentiality of patient data by anonymizing patients by a unique 28 numerical identifier. Records will be stored in a secure database. Access to the database will be 29 restricted to those directly involved in the design, implementation, and analysis of the data. No 30 patient will be identifiable in any publication arising from the study. 31 32

The reporting of Study 1 will conform to the STROBE statement [45], and reporting of Study 2 to the CONSORT statement[46]. We will disseminate our study findings widely through peer-reviewed publications and conference presentations, and make them available to guideline makers issuing recommendations on HA and THA.

#### <sup>39</sup> 40 **DISCUSSION**

41

56

#### 42 43 **Strength and weaknesses**

The design of our study has several strengths. Firstly, we have incorporated the anticipated regret model as a new method in the exploration of patients' values and preferences. Based on considerable previously published theoretical work by members of our research team [47, 48] our study will be the first to evaluate and compare its results with other methodologies. The comparison will include differences in decisions, inconsistencies, and understanding.

Secondly, in developing health scenarios we obtained input from patients who have undergone both
 total hip replacement and HA and surgeons who have expertise on total hip replacement and HA.
 These processes ensured the accuracy of our health scenarios that will be used in the study.

Thirdly, we will be the first to explore the association between influence from family and friends' previous experience on patients' values and preferences on the minimal delay time in the need for

THA surgery that patients would find acceptable to undertake HA. Indirect evidence suggests friends or family member's medical advice may influence patients' preference on medical decisions[49]. Men, African-American men in particular, are more inclined to discuss their medication concerns and to seek medical advice from trusted friends more frequently than women[50]. Women are more often inclined to solicit medical advice from their family members. Identifying the factors that may influence patients' preferences could provide valuable explanations for the variation on patients' values and preferences in future research. Knowing patients' previous perception on certain treatment options can help clinicians to explain certain things more clearly and makes clinical consultation more efficient.

Fourthly, we will check for consistency in the participants' choice on their threshold of how long HA
can delay THA they think it worthwhile proceeding. If participants have discrepant answer
between the trade off and anticipated regret exercise we will provide them the opportunity to
change their responses. Interviewers will test patients` understanding of the information presented
using standardized questions and rate respondents understanding based on their judgement. This
ensures the validity of patients' values and preference elicitation.

Our study plan also has limitations. There are conceptual limitations to the anticipated regret exercise. For instance, no one has studied the relationship between anticipated regret and actual regret subsequently experienced. If we find important discrepancies between anticipated regret and the trade-off exercise the interpretation may be challenging; in particular, it may remain uncertain which method better represents patients' real preference. Subsequent studies may be needed to address such questions arising from our results..

# <sup>29</sup>30 Implications

Although there is increasing awareness regarding shared decision-making and patient centered care, the explicit consideration of values and preferences in the care of individual patients and in the recommendations made by clinical practice guidelines remains limited [31-36].

36 Given the existing evidence, the choice between HA and THA for patients with non-advanced OA is 37 challenging. The research outlined in this protocol will provide explicit, quantitative expressions of 38 patients' valuations of their expected delay of HA on THA. This information will alert clinicians to 39 this issue and may provide guidance in their interactions with patients. It will certainly provide 40 41 crucial information for guideline developers making recommendations for clinical practice. 42 Identifying the factors that may influence patients' preferences could provide insight into variations 43 in broader perspective of patients' values and preferences in future research. 44 45

Our protocol also addresses some of the limitations of the previous studies in the field of medical
 written information regarding using adequate amount of information in patients' values and
 preference assessment. Results will have implications for clinical practice in terms of providing
 patients' with the right amount of information in the shared decision-making process.

51 52

1 2

3 4

5 6


7

8

9

- 53 54
- 55
- 56
- 57 58
- 59
- 60

$1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	Table 1: Flow chart of study design
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



5 6

Table 2 Inclusion and	d Exclusion criteria
Inclusion criteria	Exclusion criteria
(i) Patient is at least 40 years old	(i) Patient has a history of prior hip surgery
<ul> <li>(ii)Patient diagnosed by X-ray or magnetic resonance imaging (MRI) with mild or moderate (grades 1 and 2) OA based on Tonnis classification of OA[51]</li> <li>Grade 0: No signs of OA.</li> <li>Grade 1: Mild: increased sclerosis, slight narrowing of the joint space, no or slight loss of head sphericity.</li> <li>Grade 2: Moderate; small cysts, moderate narrowing of the joint space, moderate loss of head sphericity.</li> <li>Grade 3: Severe: large cysts, severe narrowing of obliteration of the joint space, no functional space, no functional sphericity.</li> </ul>	(ii) Patient is unable of complete the research tasks due to cognitive impairment or language barriers
severe deformity of the head.	
(iii) Patient has history of failed conservative management	(ii) Patient is unwilling or unable to provide informed consent.
(iv) Patient provides a written informed consent.	

For peer review only

### Page 19 of 71

#### **BMJ Open**

## Table 3: Summary of analysis plan

Study	Objectives	Outcomes	Predictors	Hypothesis	Outcome Measure	Methods of Analysis
Pilot stage						
	Determine feasibility	a) Recruitment rate		2 subjects/week	Subjects per week	
		b) Time to conduct the interview and finish all the measurement		1hour would be optimal	Interview duration	
		c) Patients attrition		Less than 5%	Patients attrition rate	
Study one: Interview Study	<u>Primary</u>	a) Delay time	age, gender, ethnicity, educational level, social economics status and medical history		Trade-off exercise	Normally distributed: mean delay time +SD; mean delay time and confidence interval If data is skewed: mode, median, and interquartile range
	<u>Secondary</u>	a) Patients' anticipated regret scores			100mm Visual Analog Scale	T-test
Study two: RCT	<u>Primary</u>	a) Patients' satisfaction on the HSs		Higher satisfaction on short version	7-point Likert type scale	T-test
	<u>Secondary</u>	a) Understandability		Both have rated as 5/7	7-point Likert type scale	T-test
		b) Information quantity		Short will be rated as 4; Long will be rated as 5;	7-point Likert type scale	T-test
		c) Patients' preference on length of format		Prefer short version	7-point Likert type scale	T-test or Mann Whitney U test
Sensitivity Analyses		Patients' satisfaction on the HSs		Higher satisfaction on short version	7-point Likert type scale	Mann–Whitney U test
		Comprehensibility		Both have 5/7	7-point Likert type scale	Mann–Whitney U test
		Information quantity		Short will be 4; Long will be 5;	7-point Likert type scale	Mann–Whitney U test
		Patients' preference on length of format		Prefer short version	7-point Likert type scale	Mann–Whitney U test

#### **Table 4: Sample size estimation tables**

		CI -years)	
0.05	2	0.5	246
		1	62
		2	16
	0.05	0.05 2	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## Table 5: Inconsistency checking

Definitions/criteria of inconsistencies	Explanations and Examples
(i) Participants anticipate regret score is higher when delay in need for THA is longer than it is at their threshold of delay time.	In the example we give that measures anticipated regret scores: we set the 5 time points as A (12 months), B (1.5 years), C (2 years), D (3 years) and E (4 years). The participant chose 2 years as the shortest delay time at which he/she can accept for processing HA. Then they placed scores 60 to represent their regret on VAS at 12months but scores 90 to represent his/her regret at 1.5years. In other words, the regret scores "r" on VAS shows: rA <rb, or="" or,="" rb<rc,="" rc<rd,="" rd<re.<="" td=""></rb,>
(ii) Participants anticipate substantial	We define substantial as the anticipated regret score on VAS at the time point that
regret although the HA would delay THA	they chose in the "trade off" exercise or any longer delay time point is bigger than (30)
longer than their threshold of delay time.	on the 100 VAS scale. The participant chose 2 years as the shortest delay time at which they can accept for processing HA. Then they still placed scores 60 to represent their regret on VAS at 2years, 3 years or 4years. In other words, the regret scores "r" on VAS shows: rC>0, OI rD>0, OR rE>0.
(iii) Patients do not anticipate any regret when delay in THA end up being shorter than what their threshold of delay time.	Comparing to the time point that participants chose in the "trade off" exercise, the anticipated regret score on VAS at any shorter delay time point is equal to (0).
than what then threshold of delay time.	For example, the participant chose 2 years as the shortest delay time at which they ca accept for processing HA. Then they place scores 0 to represent their regret on VAS at 12months and 1.5years. In other words, the regret scores "r" on VAS shows: rA=0, OR rB=0.

### Acknowledgement:

We would like to thank Matti Seppänen, Teppo Järvinen, Daniel Nightingale, Darryl Yardley, Gloria Preston, Colleen Cupido, for their feedbacks on our Health Scenarios. We would also like to thank Qi Zhou (Department of Clinical Epidemiology and Biostatistics, McMaster University) for her help on planning the statistical analyses and Peggy Austin, CCRA for her help on operating the study.

**Contributors:** YZ, KAOT, TA and GHG designed the study. YZ drafted the manuscript, with substantial inputs from TA, KAOT and GHG. DY, AT and KAOT drafted the trade-off exercise and regret exercises. BDB, GHG provided feedback on the regret exercises. MI and YZ drafted the HSs. PA, KAOT, YZ conducted the interview to test HSs. All authors contributed to the refinement of the study protocol and approved the final manuscript. GHG is the principal investigator of the study.

Funding: None

Competing interests: None declared

**Ethics approval:** The protocol has been approved by Hamilton Integrated Research Ethics Board (HIREB13-506)

**Provenance and peer review:** Not commissioned; internally peer reviewed.

**Open Access:** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http:// creativecommons.org/licenses/by-nc/3.0/.

## **Reference:**

1.	Woolf, A.D. and B. Pfleger, Burden of major musculoskeletal conditions. Bull
	World Health Organ, 2003. <b>81</b> (9): p. 646-56.

- 2. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum, 2000. **43**(9): p. 1905-15.
- 3. Brandt, K.D., *Non-surgical treatment of osteoarthritis: a half century of "advances".* Ann Rheum Dis, 2004. **63**(2): p. 117-22.
- 4. Rath, E., O. Tsvieli, and O. Levy, *Hip arthroscopy: an emerging technique and indications.* Isr Med Assoc J, 2012. **14**(3): p. 170-4.
- 5. Chen, A., et al., *The Global Economic Cost of Osteoarthritis: How the UK Compares.* Arthritis, 2012. **2012**: p. 698709.
- 6. Kurtz, S. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am, 2007. **89**(4): p. 780-5.
- 7. *7th annual report*, in *National Joint Registry for England and Wales*. 2010, National Joint Registry: Hemel Hempstead.
- 8. Kenney, N.A. and K.W. Farmer, *Minimally invasive versus conventional joint arthroplasty.* PM R, 2012. **4**(5 Suppl): p. S134-40.
- 9. DK, M. *Hip arthroscopy: Update, advances, and future applications.* AAOS Now, 2011. **5**.
- 10. Griffiths, E.J. and V. Khanduja, *Hip arthroscopy: evolution, current practice and future developments.* Int Orthop, 2012. **36**(6): p. 1115-21.
- 11. HA., L.-T., *Threshold technique*. Kattan MW, ed. Encyclopedia of Medical Decision Making. 2009, Thousand Oaks,CA: Sage Publications. 4.
- 12. Llewellyn-Thomas, H.A., et al., *Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia.* Med Decis Making, 1996. **16**(3): p. 262-82.
- 13. Ubel, P.A. and G. Loewenstein, *The role of decision analysis in informed consent: choosing between intuition and systematicity.* Soc Sci Med, 1997.
  44(5): p. 647-56.
- 14. GW., T., Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Econ Planning Sci, 1976. **10**(129): p. 36.
- 15. Zeelenberg, M., *The use of crying over spilled milk: A note on the rationality and functionality of regret.* Philosophical Psychology, 1999. **12**(3): p. 325-340.
- 16. Zeelenberg, M., *Anticipated regret, expected feedback and behavioral decision making.* Journal of Behavioral Decision Making, 1999. **12**(2): p. 93-106.

1 2 3

4

5

6 7

8

9

10

11

12 13

14

15

16

17

18 19

20

21

22

23 24

25

26

27

28

29

30 31

32

33

34

35

36 37

38

39

40

41 42

43

44

45

46

47

48 49

50

51

52

53 54

55

56

17. D., K., Maps of bounded rationality: psychology for behavioral economics. The American Economic Review, 2003.(93): p. 1449-1475. ISBT., E., Hypothetical thinking: Dual processes in reasoning and judgement. 18. 2007, New York: Psychology Press. 19. I, S., The influence of anticipating regret and responsibility on purchase decisions. | Consumer Res, 1992. 19: p. 105-118. Zeelenberg M, P.R., *A theory of regret regulation 1.0.* . | Consumer 20. Psychology, 2007. 17: p. 3-18. 21. Tsalatsanis, A. A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making. BMC Med Inform Decis Mak, 2010. 10: p. 51. 22. Bettman., J., Information processing models of consumer behavior. | Marketing Res, 1970. 7: p. 6. 23. Jacob Jacoby, D.E.S., and Carol A. Kohn., Brand Choice Behavior As a Function of Information Load: Study Ii (Abstract). Advances in Consumer Research, 1974. **01**: p. 3. 24. Hahn, M., R. Lawson, and Y.G. Lee, *The effects of time pressure and information load on decision quality.* Psychology and Marketing, 1992. **9**(5): p. 365-378. 25. Young, D.R., D.T. Hooker, and F.E. Freeberg, Informed consent documents: increasing comprehension by reducing reading level. IRB, 1990. **12**(3): p. 1-5. 26. *Comprehensive Working Group on Informed Consent in Cancer Clinical Trials* for the National Cancer Institute: Recommendations for the Development of Informed Consent Documents for Cancer Clinical Trials. . 1998 [cited 2013] April 9th]. 27. OHRP Informed Consent Frequently Asked Questions. 2008 [cited 2013 April 9th]; Available from: http://www.hhs.gov/ohrp/informconsfag.html. 28. Sharp, S.M., Consent documents for oncology trials: does anybody read these *things?* Am J Clin Oncol, 2004. **27**(6): p. 570-5. 29. Beardsley, E., M. Jefford, and L. Mileshkin, *Longer consent forms for clinical* trials compromise patient understanding: so why are they lengthening? [Clin Oncol. 2007. 25(9): p. e13-4. Soever, L.J., et al., *Educational needs of patients undergoing total joint* 30. *arthroplasty.* Physiother Can, 2010. **62**(3): p. 206-14. 31. Alonso-Coello, P. Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol. BMC Pregnancy Childbirth, 2012. 12: p. 40. Monsivais, D. and A. Reynolds, *Developing and evaluating patient education* 32. *materials.* | Contin Educ Nurs, 2003. **34**(4): p. 172-6. Schunemann, H.J. A comparison of narrative and table formats for presenting 33. hypothetical health states to patients with gastrointestinal or pulmonary *disease.* Med Decis Making, 2004. **24**(1): p. 53-60. 34. Informed Medical Decisions Foundations 2013; Available from: http://www.informedmedicaldecisions.org/. Pierce, L.L., How to choose and develop written educational materials. Rehabil 35. Nurs, 2010. 35(3): p. 99-105.

#### BMJ Open

54 55	rigu	ire 1. Anticipateu negret visual analog scale	
54	Figure 1: Anticipated Regret visual analog scale		
53	FIGU	RE LEGENDS:	
52			
51			
50			
49			
48			
47			
46			
45		1987, New York: Springer	
44	51.	D., T., Congenital dysplasia and dislocation of the hip in children and adults.	
43	۲1		
42		Osteopath Assoc, 2002. <b>102</b> (2): p. 73-8.	
41	50.	Vieder, J.N., et al., <i>Physician-patient interaction: what do elders want?</i> J Am	
40		2008 Jan 11.	
39		llln, 2008. <b>30</b> (3): p. 429-44. doi: 10.1111/j.1467-9566.2007.01064.x. Epub	
38	47.		
37	49.	Distributed decision making: the anatomy of decisions-in-action. Sociol Health	
36		<b>37</b> (4): p. 328-34.	
35		orthopaedic practice: should the orthopaedic encounter change? Injury, 2006.	
34	48.	Bryant, D., E. Bednarski, and A. Gafni, Incorporating patient preferences into	
33	40		
32	1/1	displaced femoral neck fractures. Indian J Orthop, 2012. <b>46</b> (1): p. 22-8.	
31	47.	Alolabi, B., The development of a decision aid to elicit treatment preferences for	
30		505-10.	
29		<i>controlled trials on migraine and headache.</i> J Headache Pain, 2011. <b>12</b> (5): p.	
28	40.		
27	46.	Tfelt-Hansen, P.C., CONSORT recommendations in abstracts of randomised,	
26		2009. <b>23</b> (2): p. 158.	
25		studies in epidemiology (STROBE): explanation and elaboration]. Gac Sanit,	
24	45.	Vandenbroucke, J.P., et al., [Strengthening the reporting of observational	
23	4 <del>-</del>		
22		patient's perspective. Curr Opin Rheumatol, 2006. <b>18</b> (5): p. 526-30.	
21	44.	Hawker, G.A., Who, when, and why total joint replacement surgery? The	
20	43.	Cohen, J., <i>A power primer.</i> Psychol Bull, 1992. <b>112</b> (1): p. 155-9.	
	42.	Blalock, H.M., Social Statistics. 1979, New York: McGraw-Hill.	
19	40		
18		2010: McGraw Hill.	
17	41.	G.Bluman, A., <i>Elementary Statistics: A step by step approach</i> . fifth edition ed.	
16		p. 151-65.	
15		<i>review of health state valuation techniques.</i> Pharmacoeconomics, 2000. <b>17</b> (2):	
14	40.	Green, C., J. Brazier, and M. Deverill, <i>Valuing health-related quality of life. A</i>	
12	40.		
12		<i>arthroscopy?</i> Clin Orthop Relat Res, 2011. <b>469</b> (2): p. 362-71.	
11	39.	McCarthy, J.C., et al., What factors influence long-term survivorship after hip	
10		Arthroscopy, 2010. <b>26</b> (10): p. 1370-83.	
9	30.		
8	38.	Stevens, M.S. The evidence for hip arthroscopy: grading the current indications.	
7		Times, 2003. <b>99</b> (21): p. 26-7.	
6	37.	Turnbull, A., How nurses can develop good patient information leaflets. Nurs	
5		Nephrol Nurs J, 2004. <b>31</b> (4): p. 373-7.	
4	36.	Aldridge, M.D., Writing and designing readable patient education materials.	
2 3	26	Aldridge M.D. Writing and designing readable nations education materials	
2			
1			

1	
2	
3	
4	
5 6	
7	
ratients values and preferences of the expected enfoacy of mp artifroscopy for	
osteour ministri protocor for a mattinational stractured interview subca strady complified	
<sup>9</sup> with a randomized survey on the optimal amount of information to elicit preferences 10	
11 Yuqing Zhang, Kari A.O. Tikkinen, Thomas Agoritsas, Olufemi R. Ayeni, Paul Alexander, Maha	
12 Imam, Daniel Yoo, Athanasios Tsalatsanis, Benjamin Djulbegovic, Lehana Thabane, Holger	
13 Schünemann, Gordon H. Guyatt.	
14	
15	
16 Yuqing Zhang, doctoral candidate, Department of Clinical Epidemiology and Biostatistics, McMaster University,	
17 1280 Main St., Hamilton, ON, Canada, L8S 4K1, e-mail Madisonz1220@gmail.com.	
18 Kari A.O. Tikkinen, <i>post-doctoral fellow</i> , Department of Clinical Epidemiology and Biostatistics, McMaster	
19 University, Hamilton, ON, Canada; and Department of Urology, Helsinki University Central Hospital and	
20 University of Helsinki, Helsinki, Finland.	
21 Thomas Agoritsas, research fellow, Department of Clinical Epidemiology and Biostatistics, McMaster University,	
22 Hamilton, ON, Canada.	
<ul> <li>23 Olufemi R. Ayeni, <i>consultant orthopaedic surgeon</i>, Division of Orthopaedic Surgery, Department of Surgery,</li> <li>24 McMaster University, Hamilton, ON, Canada.</li> </ul>	
<ul> <li>24 Methasier Oniversity, Hammon, ON, Canada.</li> <li>25 Paul Alexander is doctoral candidate, Department of Clinical Epidemiology and Biostatistics, McMaster University,</li> </ul>	
26 Maha Imam, student, Faculty of Pharmacy, University of Waterloo, Kitchener ON	
27 Daniel Yoo, student, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.	
28 Athanasios Tsalatsanis, <i>assistant professor</i> , Division of Evidence-based Medicine, University of South Florida,	
<ul> <li>29 Tampa, FL, USA.</li> <li>30 Benjamin Djulbegovic, <i>distinguished professor</i>, Department of Internal Medicine, University of South Florida; and</li> </ul>	
30 Benjamin Djubegović, <i>usunguisneu projessor</i> , Department of internar Medicine, Oniversity of South Piorida, and 31 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.	
32 Lehana Thabane, <i>Professor/Associate Chair</i> , Department of Clinical Epidemiology & Biostatistics, McMaster	
32 University, Hamilton, ON, Canada.	
<ul> <li><sup>34</sup> Holger Schünemann, <i>Professor and Chair</i>, Department of Clinical Epidemiology &amp; Biostatistics, McMaster</li> <li><sup>35</sup> University, Hamilton, ON, Canada.</li> </ul>	
36	
37 Gordon H. Guyatt, <i>distinguished professor</i> , Department of Clinical Epidemiology and Biostatistics, and Medicine,	
38 McMaster University, Hamilton, ON, Canada.	
39 Correspondence to:	
40 Gordon H. Guyatt, Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main Street West,	
41 Hamilton, Ontario, Canada, L8S 4K1, guyatt@mcmaster.ca. Tel: (905)525-9140 x 22900FAX: (905)524-3841	
42	
43 Keywords	
44 Patients' values and preference, Total Hip Arthroplasty, Hip Arthroscopy, Osteoarthritis, Patient	
45 Written Information, Decision Making, Uncertainty	
46 47 Word count: 5003	
47	
48	
49	
50 51	
52	
53	
53 1 54	
55	
56	
57	
58	
59	
60	

1

- 5
- 6
- 7 8
- 9
- 10
- 11

## 12 Abstract:

13

14 INTRODUCTION: Symptomatic hip osteoarthritis (OA) is a disabling condition with <sup>15</sup> up to 25% cumulative lifetime risk. Total hip arthroplasty (THA) is effective in <sup>16</sup> relieving patient's symptoms and improving function. It is, however, associated with <sup>17</sup> substantial risk of complications, pain and major functional limitation before patients 18 can return to full function. In contrast, hip arthroscopy (HA) is less invasive, and can 19 postpone THA. However, there is no evidence regarding the delay in the need for 20 21 THA that patients would find acceptable to undergo HA. Knowing patients' values 22 and preferences (VP) on this expected delay is critical when making 23 recommendations regarding the advisability of HA. Furthermore, little is known on

24 the optimal amount of information regarding interventions and outcomes needed to 25 present in order to optimally elicit patients' VP.

26

<sup>27</sup> METHODS AND ANALYSIS: We will perform a multinational, structured interview-<sup>28</sup> based survey of preference in delay time for THA among patients with non-advanced

29 OA who failed to respond to conservative therapy. We will combine these interviews 30

with a randomized trial addressing the optimal amount of information regarding 31

 $\frac{32}{32}$  interventions and outcomes required to elicit preferences. Eligible patients will be 33 randomly assigned (1:1) to either a short or a long format of health scenarios of THA 34 and HA. We will determine each patient's VP using trade-off and anticipated regret 35 exercises. Our primary outcomes for the combined surveys will be: 1) the minimal 36 delay time in the need for THA surgery that patients would find acceptable to 37 undertake HA, 2) patients satisfaction with the amount of information provided in <sup>38</sup> the health scenarios used to elicit their VPs.

39

40 ETHICS AND DISSEMINATION: The protocol has been approved by Hamilton 41 Integrated Research Ethics Board (HIREB13-506). We will disseminate our study 42  $\frac{42}{43}$  findings through peer-reviewed publications and conference presentations, and make 44 them available to guideline makers issuing recommendations addressing HA and 45 THA.

2

- 46
- 47
- 48 49
- 50
- 51

- 53 54
- 55
- 56
- 57
- 58
- 59 60

#### 10 BACKGROUND 11

12

#### 13 Osteoarthritis and surgical options

14 Osteoarthritis: Osteoarthritis (OA) is the most common form of chronic arthritis. Approximately 15% of 15 men and women suffer from symptomatic OA[1], representing a large burden on patients, the 16 healthcare system and society. Symptomatic hip OA is a particularly disabling condition with a cumulative lifetime risk of up to 25%. Conservative management of hip OA includes exercise, 17 18 weight reduction, physical therapy and medications focusing on relieving symptoms, improving 19 joint function, and optimizing quality of life[2]. Pharmacological and non-pharmacological interventions for severe OA are, however, substantially less effective than surgical treatment[3]. 20

Consequently, most patients with severe hip OA eventually need total hip arthroplasty (THA)[3]. 21

<sup>22</sup> Total hip arthroplasty: With an aging population increasingly interested in staying physically active

23 [4], the frequency and cost of THA continues to grow. Currently more than a half million THA <sup>24</sup> procedures are performed annually in the UK and USA alone, and in 2010 the global market was 25 estimated as high as 4.7 billion USD[5].

26

27 After failure of conservative treatment, THA is usually effective in relieving patient's symptoms

28 and improving function, with more than 95% prosthesis survivorship at 10-year follow-up and more

29 than 80% survivorship at 25-year follow-up[6, 7]. However, THA is also a major procedure,

30 associated with substantial risk of complications, and with weeks of pain and major functional 31 limitations before patients can return to full function. Therefore, patients and caregivers are

32 interested in less invasive interventions that could postpone THA.

33

34 Hip arthroscopy: Less invasive interventions include arthroscopy, partial replacements, and bone-

35 preserving techniques. They have shown varying success rates among OA patients[8]. Hip

36 the last of the

the lack of high quality evidence, the number of HAs performed is expected to double in the United

37 States in 2013 compared to 2011[9]. HA is used to treat intra articular pathology of the hip, 38 including mild hip OA. Compared to THA it has the advantages of being minimally invasive and

<sup>39</sup> having fewer complications [10]. Compared to THA, arthroscopy may help patients achieve higher

<sup>40</sup> level of function more quickly with, over the short term less restriction on exercise. The expectation,

41 however, is that patients' underlying osteoarthritis will progress, and THA will ultimately become

42 necessary. The question then arises: what delay in the need for THA would warrant a patient 43 undergoing HA? This is a question of values and preferences.

44

### 45 Measuring patients' values and preference

46

There are a number of techniques available for eliciting patients direct choices of which the 47 probabilistic version of the Threshold Technique (TT) also called probability trade-off (PTO) 48 exercise is widely used [11]. Following descriptive and probabilistic information regarding benefits 49 and harms associated with treatment choices - for example treatment A and B - in which the

50 relative benefits of treatment A versus B are large, the respondent is asked to choose one option. 51 Typically, patients will choose treatment A. The interviewer then presents an alternative situation

52 in which the relative benefits of A versus B are very small, and patients typically choose B. The 53

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

interviewer than presents a small reduction in the probability of benefits, relative to the first scenario, for option A. If the patient continues to choose A, the next scenario presents a small increase in the benefits of A versus B relative to the second scenario. The process is repeated until 10 the indifference point between A and B is established (ping pong approach)[12]. 11

12 Utility elicitation uses a very different approach, presenting health states and using one of a 13 14 variety of techniques to elicit the respondent's rating of the value of the health state on a scale 15 between death (typically 0) and full health (typically 1.0 or 100). The patients' responses are used to 16 build a decision model that calculates the treatment option that, given the patient's utilities, 17 achieves the maximum utility-adjusted outcome [13, 14].

8

9

18 Complementary approaches to assess patients' decision-making integrate emotional aspects of the <sup>19</sup> process. One such approach focuses on regret, an aversive emotion people experience when they 20 believe their current situation would have been better had they acted differently in the past[15, 16]. 21 In theory, regret is influenced by both intuitive, affect-based, and analytical, deliberative 22 processes [17, 18]. Reflecting on the anticipated regret of particular decisions (e.g. choosing A versus 23 B in the example above) may alert people to the choice that would be most likely to avoid this 24 aversive emotion[19, 20]. The anticipated regret theory-based approach preserves a rational 25 decision-making framework, while allowing anticipation of the effect of the decision on 26 emotions[21].

27

Using both (direct choice) trade-off and anticipated regret exercises, our study will provide 28 empirical evidence regarding the delay in the need for THA that patient would find acceptable to 29

undergo HA. 30

#### 31 Amount of information presented to elicit patients' values and preference 32

33 The choices patients make are critically dependent on how the health scenario (HS) that

34 characterizes the processes and outcomes of the alternative management options (A and B in the

 $^{35}$  above – THA and HA in the current project) are presented. Research in marketing has addressed

36 some of the relevant issues. Information-processing framework[22] suggests that that there are

37 limits to the human ability to assimilate and process information, and that once these limits are

38 surpassed behavior becomes confused and dysfunctional[23]. Evidence suggests an inverted U-

39 shaped relationship between information available and decision quality, in which individuals with 40 too little or too much information made poorer decisions than those with an intermediate amount of

41 information [24, 25].

42

43 Other indirect evidence comes from research on written consent forms [26, 27]. Individuals often 44 skim over consent forms for clinical trials in oncology if they are longer than 1,000 words or 4 45 pages[28]. Twenty-seven oncology trials showed that patients obtain significantly higher objective knowledge when the consent form page count was seven or less [29]. 46

47

In the area of pharmaceutical product choice, participants have had better understanding of shorter 48 and easier information presentations[25]. One might expect, however, that if the information 49 becomes too scanty, decision quality will deteriorate. 50

## <sup>51</sup> Patients' values and preferences on osteoarthritis surgical options

<sup>52</sup> Given the existing evidence, both HA and THA represent reasonable choices for patients with non-53

- 54
- 55
- 56
- 57
- 58
- 59
- 60

1

- 5
- 6 7

8

advanced OA. The choice may, however, be challenging. On one hand, HA is likely to achieve only transient improvement in function. On the other hand, the morbidity associated with THA is 9 substantial.

10

11 Therefore, one of the key aspects in the choice between HA and THA is the duration of delay in the 12 need for THA that patients may achieve with HA. If patients demand a delay time much greater 13 than HA can realistically achieve, the procedure should seldom be considered. On the other hand, if 14 patients would be satisfied with much shorter delay time, the procedure should be frequently 15 considered. There is currently no empirical evidence addressing patients' values and preferences 16 regarding the delay they would demand to undertake HA. Knowing typical patients' values and 17 preferences regarding this expected delay is likely to be helpful for patients and health care 18 providers in the clinical encounter and for guideline panelists when making recommendations regarding the advisability of HA.

19

20 The assessment of patients' values and preferences will be valid only to the extent patients receive 21 sufficient accurate information on the outcomes of available treatment options presented in ways 22 that they can easily process. Thus far, only limited indirect evidence informs us on the optimal 23 amount of information to provide in scenarios when eliciting patients' preferences.

24 25 Our study will provide direct empirical evidence on the optimal amount of information to provide 26 when eliciting patients' values and preferences. It may also provide insight into the amount of 27 information to provide in shared-decision making, although our study only indirectly addresses that issue.

28

#### 29 **OBJECTIVES** 30

31 General Objective: The purpose of this study is to improve the management of patients with non-32 advanced symptomatic hip osteoarthritis (OA) who failed conservative treatment by determining 33 their values and preferences regarding the choice between immediate total hip arthroplasty (THA) 34 versus hip arthroscopy (HA).

35

36 In the **Pilot stage** of our study, we will assess the following feasibility issues: (i) recruitment rate; 37 (ii) length of time to conduct the interview and fill out all the study measurements; (iii) potential 38 personnel and data management issues.

39

40 In <u>Study 1</u> – our primary objective is to determine the minimal delay time in the need for THA 41 surgery that patients would find acceptable to undertake HA (which we will refer to as the "delay 42 time"). Secondary objectives include assessing patients' anticipated regret if the delay would differ 43 from their expectations, as well as potential determinants of their preference (e.g., age, gender, educational level, and socioeconomic status). 44

 $^{45}$  In <u>Study 2</u> – our objective is to assess the ease of understanding, optimal quantity of information, 46 and patients' satisfaction regarding alternative formats of the HSs used to elicit their preferences. 47

5

#### 48 METHODS

- 49 50

## 51 Study design

- 52 53
- 54
- 55
- 56
- 57
- 58
- 59

8

1

#### Pilot study

9 In a pilot study, we will assess the following feasibility issues: (i) recruitment rate; (ii) length of 10 time to conduct the interview and fill out all the study measurements; (iii) potential personnel and 11 data management problems in real-life setting. We will perform this study at the outpatient orthopedic clinic of the McMaster University Medical Center (Hamilton, ON, Canada). 12

13

Study 1: We will perform a multinational, cross-sectional, structured interview-based survey to 14 assess the delay in THA that patients would demand to choose HA. 15

16

Study 2: Within Study 1, we will conduct a randomized trial comparing a short version versus a 17

long version of HA and THA health scenarios. 18

Table 1 shows the study flow. 19

20 Setting: The study will take place at McMaster University Medical Center, Hamilton, Canada; St. 21 Michael's Hospital, Toronto, Canada; Hospital de Sant Pau, Barcelona, Spain; and Sorocaba

22 Hospitals, São Paulo, Brazil.

#### 23

#### 24 Study population

25 The population of interest consists of adults diagnosed with non-advanced hip OA. Table 2 presents 26 the detailed inclusion and exclusion criteria.

27

#### 28 Recruitment strategy

29 We will prospectively identify consecutive patients confirmed with non-advanced hip OA referred

30 for consideration of HA. The orthopedic surgeon will send a letter in advance of their visit to inform

31 patients about our research project and the possibility of being approached by our research

32 assistant (RA) for this study. The RA will then make initial contact with all the patients by phone

to explain the purpose of the study. When the patients come to the orthopedic clinic, we will ask 33 34 patients for their written informed consent.

#### 35 **Participants interview** 36

**37** Baseline information

38 We will document patients' age, gender, ethnicity, educational level (not completed high school; 39

40 completed high school only; some college/university; completed college or university), yearly income,

and their impression of the experience of close relatives or friends who have undergone HA or THA 41

(categorized as extremely dissatisfied; dissatisfied; neutral; satisfied; extremely satisfied, or 42

differing across individuals). 43

#### 44 Health scenarios

45

46 The health scenarios are designed to inform patients of the surgical options. Based on available 47 evidence [30] we will include the following five sections in the HSs for THA and HA: [26] Brief 48 introduction to the surgery; [31] Description of the surgical procedure; [iii] Post-operative recovery 49 and rehabilitation; [32] Expected benefits; [v] Risks and potential complications. (See appendix: 50 Script #1: Health scenarios)

52 The short versions have approximately 850 words and the long versions approximately twice the

6

53

- 54
- 55
- 56
- 57 58
- 59
- 60

1 2 3 4 5 6 7 number of words; both versions use the same sub-headings. 8 9 To ensure we present accurate estimates of benefits and risks of THA and HA to patients[33], 10 conveyed in the most simple and easy-to-understand way possible, we applied a rigorous process to 11 develop these health scenarios. 12 Firstly, we performed a search on PubMed to retrieve relevant content from systematic reviews, 13 14 randomized control trials (RCT), and observational studies. Evidence from systematic reviews, 15<sup>preferred</sup> if available. 16 Secondly, we reviewed THA booklets from Brant Community Healthcare System, Hamilton Health 17 Sciences, Joseph Brant Memorial Hospital, Niagara Health System, St. Joseph's Healthcare 18 Hamilton, National Institute of Arthritis and Musculoskeletal, and Skin Diseases (NIAMS) to 19 inform SCENARIO design and content. For both THA and HA, we also reviewed information from 20 other sources such as the Informed Medical Decisions Foundations (IMDF) [34] and National 21 Institute of Health for both THA and HA HSs (when available). 22 23  $\frac{24}{100}$  Thirdly, we considered the following strategies to increase the ease of understanding and 25 readability of our scenarios[35]. We focused the material on key concepts with consistent and 26 simple words aiming for 1–2 syllables[32, 36]. A clear topic sentence are used at the beginning of 27 each sub-heading with following details and examples[37]. We <del>also</del>-used conversational style with 28 the second person point of view (i.e., "you")[37]. We also used the Flesch-Kincaid Grade Level test in 29 Microsoft Word 2011 to ensure the English is understandable for people with grade 10 level 30 education. 31 32 Finally, we revised our scenarios based on feedback from 15 orthopedic surgeons (8 of them 33 commented on THA, and 7 of them commented on HA); from 2 focus group (3 patients in each 34 group) and 4 individual interviews with a total of 10 patients (5 for each surgery) who had undergone THA or HA; and 5 physiotherapists. 35 36 For the Spanish and Portuguese part of the study, an experienced medical translator will 37 undertake the initial translation. In each language, one clinical epidemiologist and one orthopedic 38 surgeon, native in the non-English language and fluent in English, will check the translation and 39 discuss potential revisions with the translator. After we obtain the Spanish and Portuguese 40 versions, back translations will be performed and checked by the epidemiologist and the orthopedic 41 surgeon, with further revisions to the Spanish and Portuguese versions if necessary. 42 43 Randomization of the health scenarios 44 45 Participants will be randomized to receive the short format or long formats of the scenarios in coded 46 packages that the interviewer will open at the start of the interview. We will use central 47 randomization at McMaster University using an allocation ratio of 1:1 with random blocks size 48 (2,4,8). 49 We will ask participants to read hard copies of the corresponding health scenarios (short or long). 50 51 At the end of the interview - i.e., after the trade-off exercise, anticipated regret exercise, and a 52 check for consistency and understanding that we will describe subsequently – the RA will show 53 7 54 55 56 57 58 59 60

patients in each group the version they have not yet seen and ask about their preferred format. If participants have more content questions regarding the scenarios, the RA will instruct the patient to ask the orthopedic surgeon for further assistance in the patient-doctor consultation after the 10 interview. 11

#### 12 Trade off exercise

13 After participants have read the initial health scenario (short or long version), we will assess the 14 minimum acceptable delay (delay time) in THA that patients would find acceptable to undergo HA. 15 We will use the following generic questions: "By how much longer should the arthroscopy postpone 16 the need for hip replacement surgery for you to consider the hip arthroscopy worthwhile? Would 17 you choose hip arthroscopy if it would delay the need for total hip replacement by [delay time in 18 months/year]?" We will offer a range of delay times, alternating between short and long times in a 19 ping-pong strategy, e.g.: 3 months – 12 years – 6 months – 10 years, etc. We will progressively 20 narrow the range of the alternatives offered as we repeat the exercise.

#### 21 22

8

9

23 The lower bound of delay time offered (i.e. 3 months) is just below the anticipated least stringent 24 participants' demand and also corresponds to the shortest follow-up time in studies that evaluate 25 the efficacy of HA[38]. For the upper bound initially offered, the literature suggests that the most 26 optimistic estimate of the time which HA may delay THA is approximately 10 years[39]. If patients 27 are not satisfied with the upper boundary of the delay time - that is, they would demand a delay of 28 more than 12 years before they would undergo HA – there will be provision for them to express this 29 <sup>preference.</sup>

30

Anticipated regret exercise 31

<sup>32</sup> Following the trade-off exercise, we will assess participants' anticipated regret associated with 33 choosing or not choosing a treatment alternative. We will measure anticipated regret using a 100 34 mm visual analog scale (VAS) called the Feeling Thermometer (FT)[40], anchored at no regret (0) to 35 maximum regret (100). (Figure 1 anticipated regret VAS)

36

We will assess anticipated regret at five different time points (the patient personal threshold 37

38 determined during trade-off exercise, as well as two shorter and two longer options). For example, if

39 the patient chose 2 years as their shortest delay time, we will ask her: "How much regret would you

 $\frac{3}{40}$  feel about choosing hip arthroscopy if you need to have a total hip replacement surgery after 12

months/1.5 years/2 years/3 years/4 years?. This process allows us to check for inconsistent 41

answers (see below). 42

### 43 Blinding

 $^{44}$  Since this is a patient educational trial, the interviewers (data collectors) cannot be blinded. The 45 orthopaedic surgeons, patients (outcome assessors), and data analysts will be blinded to sequence of 46 giving HSs.

47

#### 48 49 Outcomes

50

53

54

51 Our primary outcome measures for the pilot stage regarding feasibility issues are the recruitment 52 rate, length of time to conduct the interview and fill out all the outcome measurements. We will

- 55 56
- 57 58
- 59
- 60

53

7 explore the potential personnel and data management problems in the McMaster Medical center to
8 ensure the quality of the definitive stage of our study. We will note the number of participants
9 enrolled each week. The mean and standard error of the center's recruitment rate over recruitment
10 period will be our study recruitment rate. We will also calculate the percentage of eligible patients
11 who agree to participate. We will time the length of the interview, the length of finishing
12 interviewers' administrated or patients' administrated questions.

We will consider recruitment feasible for a large study if we will be able to recruit two patients at McMaster Medical center per week (i.e., 100 subjects over 50 weeks). <u>We will consider the pilot</u> <u>stage (approximately 2 months) to be successful, and a large multicenter RCT to be feasible if: (i) we</u> <u>successfully recruit 20% of the patients according to our estimated sample size in 2 months; (ii) we</u> <u>will be able to finish the interview and all the outcome assessment in approximately one hour. (See</u> <u>table 3 for outcomes and corresponding objectives)</u>

20 We considered the pilot stage (approximately 2 month) to be successful, and a large multicenter
21 RCT to be feasible; if we successfully (i) recruit 20% of our estimated sample size; (ii) we will be able
22 to finish the interview and all the outcome assessment approximately one hour. (See table 3 for
23 outcomes and corresponding objectives).

We will modify our protocols in response to limitations with respect to excessive length of the interveiewinterview, difficulties with comprehension or ambiguities in the questions, and personnel or data management problems identified in the pilot.

28 For Study 1, our outcomes are:

30 Primary outcome: the minimal delay in the need for THA surgery that patients would find 31 acceptable to undertake HA (which we will refer to as the "delay time").

Secondary outcomes:

- (i) Independent predictors of the primary outcome includ<u>eing</u> age, gender, educational level, and socioeconomic status, and family/friends' experiences withon -preervious THA or/and HA.
   (ii) Patients' anticipated regret scores on a 100mm VAS at five different time points (the one
- (ii) Patients' anticipated regret scores on a 100mm VAS at five different time points (the one patients chose in the trade-off exercise, and two shorter and two longer options).
   39

40 For Study 2 our outcomes are:

41 Primary outcome: patients' satisfaction on the scenarios after reading the initial scenarios. 42 Interviewers will determine the degree of satisfaction participants place in the scenarios using a 7-43 point Likert-type scale with response options: completely dissatisfied, mostly dissatisfied, 44 somewhat dissatisfied, neither satisfied nor dissatisfied, somewhat satisfied, mostly satisfied, 45 completely satisfied. 46 Secondary outcomes: 47 1. Ease of understanding: we will assess participants impression of each of understanding of 48 each scenario using a 7-point Likert-type scale with response options: extremely hard, very 49 hard, hard, not easy not hard, easy, very easy, extremely easy. 50 2. Information quantity: we will ask participants to rate the quantity of the information 51 displayed in the initial presented scenario by a 7-point Likert-type scale with response 52

9

Formatted: Font: (Default) Century Schoolbook, 12 pt, Not Italic, Font color: Auto, Pattern: Clear

- 5 6 7 options: much too little, somewhat too little, slightly too little, about right amount of 8 information, slightly too much, somewhat too much, much too much. 9 3. Patients' preference on length of format: After patients finishes reading both the long and 10 short versions of scenarios we will ask them about their preference for the short or long 11 version, using a 7-point Likert-type scale with response options: short version much better,
  - 12 short version somewhat better, short version little better, no preference, long version little 13 better, long version somewhat better, long version much better. 14

#### 15 Data collection

16 A trained interviewer will collect all the outcomes by completing the case-report forms (CRFs) at 17 the end of the interview. No follow-up and further data collection will be involved.

#### 18 Sample size calculation 19

20 Studv 1: 21

22 Due to the paucity of similar studies in literature, we are unable to estimate the standard error (SE) 23 of delay time precisely. If the data is normally distributed, 99.7% of the area under of the normal 24 distribution curve lies within 3 standard deviations[41]. We assume the range of delay time (12 25 years) will be normally distributed. Therefore, we anticipate a SD of approximately 2 years. We 26 developed the sample size estimation table using the SD and varying the confidence interval 27 around the mean to obtain sample size using the formula below[42] (Table 4).

$$\frac{28}{29}_{30} n - \frac{4z_{1-\frac{\alpha}{2}}^{2}\sigma^{2}}{L^{2}}$$

31 N represents the sample size,  $\sigma$  represents the SE, L represents the confidence interval around the 32 mean. 33

34 At the end of the pilot stage we will calculate the SE of delay time in the 20 patients as a reference 35 point to modify our earlier sample size estimation for the definite study.

36 37 Study 2:

38

Based on Cohen's rule of sums [43], we used "SD=0.5" to calculate the sample size to achieve a 39

medium effect size. With a sample size of 62 in each group the trial is powered to detect a medium 40

effect size of mean = 0.5 or larger given 80% power level and  $\alpha$  = 0.05 in a two-sided test. 41

Considering the result will be obtained immediately after the assessment and all outcomes will be

42 interviewer administrated, we anticipate no loss to follow-up. We also made a sample size  $^{43}$  estimation table with different confidence intervals around the mean (Table 4). Sample size  $^{44}$  calculation is performed using SPSS (Statistical Package for the Social Sciences) version 21.0 for

- 45 Windows.
- 46

47 After finishing the pilot stage of our study, we will compare the estimated sample size for study 1 48 and 2 and take the larger number as our final sample size for the combined studies.

10

#### 49 50 Data analysis and interpretation

51 Study 1 52

53

54

55

56

57

58

1 2 3 4 5 6 7 8 Description of baseline characteristics: 9 We will present patients' age, gender, ethnical / cultural group, educational level, socioeconomic 10 status and medical history[44]. Means and standard deviations (SD) will be used to present 11 continuous variables and two-tailed T-test (or Mann-Whithey U test for non-normal distributions) 12 to detect significant differences (p<0.05) between group means. We will use proportions and 13 frequency tables to present categorical variables and a two-tailed Fisher's Exact test will be used to 14 detect statistically significant (p<0.05) differences between two groups. 15 16 Primary and secondary outcome(s): We will assess the distribution of the mean delay time and represent it graphically using 17 18 histogram(s). If the data is normally distributed we will present the mean delay time and SD. We will also estimate 95% confidence intervals of the mean respectively. If the data is skewed, we will 19 present the mode, median, and interquartile range. 20 21 Multiple variable linear regressions will be undertaken to determine statistically independent 22 predictors of the threshold of delay time. In this analysis, the delay time will be the dependent 23 variable and the independent variables will be the previous experience of THA and HA in friends 24 and family, age, gender, socioeconomic status, educational level. 25 26 After presenting the health scenarios and recording participants' response with both "trade off" and 27 anticipated regret exercise, we will compare results between these two measurements of 28 participants' values and preferences. 29 30 We have defined three possible patterns of inconsistent response (See table 5 Inconsistency 31 checking). If the participants' answers fall into any of these patterns, interviewers will review 32 participants' original answers without, however, implying that they must modify their original 33 choices. If the participants confirm their original answers, interviewers will determine and record the reasons of participants' inconsistent choices based on participants' explanation. If patients, 34 following review of the relation between their trade off and regret choices, desire to modify their 35 chosen delay time, interviewers will repeat the trade-off exercise. 36 37 For the analyses above, we will determine whether the delay time differs between those with an <sup>38</sup> apparently high level of understanding and those who demonstrate any of the inconsistencies 39 depicted in Table 2. If we find an important discrepancy between the results of patients categorized 40 as understanding and not understanding, we will focus our primary analysis on the group of 41 patients who apparently have a high level of understanding. 42 43 44 Study 2 45 Baseline characteristics description 46 We will summarize patients' age, gender, ethnical / cultural group, educational level, social 47 economics status in a table. 48 49 Primary and secondary outcome(s): 50 51 Our primary outcome will be participants' satisfaction of the health scenarios assessed by a 7-point 52 Likert scale. We will also visualize it by using histogram(s). We will conduct a two-sided student T-53 54 55 56 57 58 59 60

test will to compare mean satisfaction scores and ease of understanding between the short and long scenarios. We will also calculate the mean difference and 95% confidence intervals.

10 For information quantity, we will present a histogram depicting the proportion of participants' 11 choice in each category. We will apply 2 approaches to analyze information quantity at the first 12 assessment. First, we will determine if the distribution between two groups differ by greater than 13 chance with two-sided student T-test (if its normally distributed) or Mann-Whitney U test(if its not 14 normally distributed). Second, using a chi-square test we will determine if the proportions of 15 participants who choose "about the right amount of information", in comparison to those who choose 16 other response options, differ between groups.

17

8

9

We will use 2 approaches to compare participants' preferences for the short versus long formats after showing patients both scenarios. First, we will treat the outcomes on the 7-point scale as multinomial ordered outcomes. We will analyze the result using Mann-Whithey U test. Second, we will use a more conservative approach and compare the proportions of participants who prefer the short format to the proportion of participants who have either no preference or prefer the long

<sup>22</sup> format by using a chi-square test. (Table 3: Summary of analysis plan).

23

### <sup>24</sup> ETHICAL AND DISSEMINATION

25 This study will be performed in accordance with established guidelines for research involving 26 human patients. The proposed study does not pose any safety risks to participating patients. The 27 protocol has received Research Ethics Board approval at Hamilton Health Sciences (McMaster 28 University Medical Centre) and will be submitted for approval at the other participating sites. The 29 research objectives and study intervention will be explained to the patient verbally and in writing 30 in easily comprehensible language. Written informed consent will be obtained from all patients. 31 Patients will be informed of their right to ask for further information at any time and to withdraw 32 from study without prejudice to their future care. In the unlikely event that participants find 33 considering the above scenarios upsetting, the interview will be immediately stopped and support 34 offered. We will ensure confidentiality of patient data by anonymizing patients by a unique 35 numerical identifier. Records will be stored in a secure database. Access to the database will be 36 patient will be identifiable in any publication arising from the study.

38

<sup>38</sup> The reporting of Study 1 will conform to the STROBE statement [45], and reporting of Study 2 to <sup>39</sup> the CONSORT statement[46]. We will disseminate our study findings widely through peer-reviewed <sup>40</sup> publications and conference presentations, and make them available to guideline makers issuing

41 recommendations on HA and THA.

#### 42 43 DISCUSSION

44

## <sup>45</sup> Strength and weaknesses

46 The design of our study has several strengths. Firstly, we have incorporated the anticipated regret

47 model as a new method in the exploration of patients' values and preferences. Based on

48 considerable previously published theoretical work by members of our research team [47, 48] our

49 study will be the first to evaluate and compare its results with other methodologies. The

50 comparison will include differences in decisions, inconsistencies, and understanding.

51

52 Secondly, in developing health scenarios we obtained input from patients who have undergone both

12

- 54 55
- 56
- 57
- 58
- 59
- 60

5	
6	
7	total hip replacement and HA and surgeons who have expertise on total hip replacement and HA.
8	These processes ensured the accuracy of our health scenarios that will be used in the study.
9	
1	

11 Thirdly, we will be the first to explore the association between influence from family and friends'
12 previous experience on patients' values and preferences on the minimal delay time in the need for
13 THA surgery that patients would find acceptable to undertake HA. Indirect evidence suggests
14 friends or family member's medical advice may influence patients' preference on medical
15 decisions[49][, 2008 #442]. Men, African-American men in particular, are more inclined to discuss
16 their medication concerns and to seek medical advice from trusted friends more frequently than
17 women[50]. Women are more often inclined to solicit medical advice from their family members.
18 Identifying the factors that may influence patients' preferences could provide valuable explanations
19 perception on certain treatment options can help clinicians to explain certain things more clearly
20 and makes clinical consultation more efficient.

22 Fourthly, we will check for consistency in the participants' choice on their threshold of how long HA 23 can delay THA they think it worthwhile proceeding. If participants have discrepant answer 24 between the trade off and anticipated regret exercise we will provide them the opportunity to 25 change their responses. Interviewers will test patients' understanding of the information presented 26 using standardized questions and rate respondents understanding based on their judgement. This 27 ensures the validity of patients' values and preference elicitation.

28 OThere are some weaknesses in our study plan also design has limitations as well. There are 29  $3\phi$  conceptual limitations to the anticipated regret exercise. For instance, no one has studied the relationship between anticipated regret and actual regret subsequently experienced. utilization of 31 the anticipated regret exercise might bring in some conceptual difficulties for patients to 32 understand the questions. If we find important discrepancies between anticipated regret and The 3\$ possible discrepancy between the trade-off exercise and the anticipated regret exercise may also be 34 the interpretation may be challenging; in particular, it may remain uncertain hard to interrupt and 35 to draw conclusion on which of the method better represents patient's' real preference. Subsequent 36 studies may be needed to address such <del>answer further</del> questions arising from our results.the 37 results of our proposed studies. 38

### <sup>39</sup> Implications

40 Although there is increasing awareness regarding shared decision-making and patient centered 41 care, the explicit consideration of values and preferences in the care of individual patients and in 42 the recommendations made by clinical practice guidelines remains limited [31-36]. 43

44 Given the existing evidence, the choice between HA and THA for patients with non-advanced OA is
45 challenging. The research outlined in this protocol will provide explicit, quantitative expressions of
46 patients' valuations of their expected delay of HA on THA. This information will alert clinicians to
47 this issue and may provide guidance in their interactions with patients. It will certainly provide
48 crucial information for guideline developers making recommendations for clinical practice.
49 Identifying the factors that may influence patients' preferences could provide insight into variations
50 in broader perspective of patients' values and preferences in future research.


51

51 Our protocol also addresses some of the limitations of the previous studies in the field of medical 52 written information regarding using adequate amount of information in patients' values and 53 13

- 55
- 5
- 56
- 57
- 58
- 59

**BMJ Open** 

<sup>34</sup> Table 1: Flow chart of study design



#### Table 2 Inclusion and Exclusion criteria

Inclusion criteria	Exclusion criteria
(i) Patient is at least 40 years old	(i) Patient has a history of prior hip
	surgery
(ii)Patient diagnosed by X-ray or magnetic	(ii) Patient is unable of complete the
resonance imaging (MRI) with mild or	research tasks due to cognitive
moderate (grades 1 and 2) OA based on	impairment or language barriers
Tonnis classification of OA[51]	
Grade 0: No signs of OA.	
Grade 1: Mild: increased sclerosis, slight	
narrowing of the joint space, no or slight	
loss of head sphericity.	
Grade 2: Moderate; small cysts, moderate	
narrowing of the joint space, moderate loss	
of head sphericity.	
Grade 3: Severe: large cysts, severe	
narrowing of obliteration of the joint space,	
severe deformity of the head.	
(iii) Patient has history of failed	(ii) Patient is unwilling or unable to
conservative management	provide informed consent.
(iv) Patient provides a written informed	
consent.	

 Figure 1: Anticipated Regret visual analog scale i or or or only

See separate file

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

### Table 3: Summary of analysis plan

Study	Objectives	Outcomes	Predictors	Hypothesis	Outcome Measure	Methods of Analysis
Pilot stage						
	Determine feasibility	a) Recruitment rate		2 subjects/week	Subjects per week	
		b) Time to conduct the interview and finish all the measurement		1hour would be optimal	Interview duration	
		c) Patients attrition		Less than 5%	Patients attrition rate	
Study one: Interview Study	<u>Primary</u>	a) Delay time	age, gender, ethnicity, educational level, social economics status and medical history		Trade-off exercise	Normally distributed: mean delay time +SD; mean delay time and confidence interval If data is skewed: mode, median, and interquartile range
	<u>Secondary</u>	a) Patients' anticipated regret scores			100mm Visual Analog Scale	T-test
Study two: RCT	<u>Primary</u>	a) Patients' satisfaction on the HSs		Higher satisfaction on short version	7-point Likert type scale	T-test
	<u>Secondary</u>	a) Understandability		Both have rated as 5/7	7-point Likert type scale	T-test
		b) Information quantity		Short will be rated as 4; Long will be rated as 5;	7-point Likert type scale	T-test
		c) Patients' preference on length of format		Prefer short version	7-point Likert type scale	T-test or Mann Whitney U test
Sensitivity Analyses		Patients' satisfaction on the HSs		Higher satisfaction on short version	7-point Likert type scale	Mann–Whitney U test
		Comprehensibility		Both have 5/7	7-point Likert type scale	Mann–Whitney U test
		Information quantity		Short will be 4; Long will be 5;	7-point Likert type scale	Mann–Whitney U test
		Patients' preference on length of format		Prefer short version	7-point Likert type scale	Mann–Whitney U test

#### Table 4: Sample size estimation tables

Study	æ	SD	<i>L</i> (width of CI -years)	Sample size
Study one	0.05	2	0.5	246
			1	62
			2	16

Study	<u>ax</u>	β	SD	Difference	Sample size (Per arm)	
Study two	0.05	0.8	1	0.5	62	
				1	16	
				2	4	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1
2
2 3
4
5
6
7
1
8
9
10
11
12
12
13
14
15
16
17
18
10
19
$ar{3}$ 4 5 6 7 8 9 10 11 2 3 14 5 16 7 8 9 21 22 32 25 26 7 8 9 31 32 33 4 5 6 7 8 9 31 23 34 5 6 7 8 9 30 1 2 3 34 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 30 1 32 33 4 5 6 7 8 9 10 1 20 1 20 1 20 1 20 1 20 1 20 1 20
21
22
23
2/
24
25
26
27
28
29
20
30
31
32
33
34
35
36
00
37
38
39
40
41
41
43
44
45
46
47
48
<u>4</u> 0

## Table 5: Inconsistency checking

Definitions/criteria of inconsistencies	Explanations and Examples
(i) Participants anticipate regret score is higher when delay in need for THA is longer than it is at their threshold of delay time.	In the example we give that measures anticipated regret scores: we set the 5 time points as A (12 months), B (1.5 years), C (2 years), D (3 years) and E (4 years). The participant chose 2 years as the shortest delay time at which he/she can accept for processing HA. Then they placed scores 60 to represent their regret on VAS at 12months but scores 90 to represent his/her regret at 1.5years. In other words, the regret scores "r" on VAS shows: rA <rb, or="" or,="" rb<rc,="" rc<rd,="" rd<re.<="" th=""></rb,>
(ii) Participants anticipate substantial regret although the HA would delay THA longer than their threshold of delay time.	We define substantial as the anticipated regret score on VAS at the time point that they chose in the "trade off" exercise or any longer delay time point is bigger than (30) on the 100 VAS scale. The participant chose 2 years as the shortest delay time at which they can accept for processing HA. Then they still placed scores 60 to represent their regret on VAS at 2years, 3 years or 4years. In other words, the regret scores "r" on VAS shows: rC>0, OR rD>0, OR rE>0.
(iii) Patients do not anticipate any regret when delay in THA end up being shorter than what their threshold of delay time.	Comparing to the time point that participants chose in the "trade off" exercise, the anticipated regret score on VAS at any shorter delay time point is equal to (0). For example, the participant chose 2 years as the shortest delay time at which they can accept for processing HA. Then they place scores 0 to represent their regret on VAS at 12months and 1.5years. In other words, the regret scores "r" on VAS shows: rA=0, OR rB=0.
	20

#### Acknowledgement:

We would like to thank Matti Seppänen, Teppo Järvinen, Daniel Nightingale, Darryl Yardley, Gloria Preston, Colleen Cupido, for their feedbacks on our Health Scenarios. We would also like to thank Qi Zhou (Department of Clinical Epidemiology and Biostatistics, McMaster University) for her help on planning the statistical analyses and Peggy Austin, CCRA for her help on operating the study.

**Contributors:** YZ, KAOT, TA and GHG designed the study. YZ drafted the manuscript, with substantial inputs from TA, KAOT and GHG. DY, AT and KAOT drafted the trade-off exercise and regret exercises. BDB, GHG provided feedback on the regret exercises. MI and YZ drafted the HSs. PA, KAOT, YZ conducted the interview to test HSs. All authors contributed to the refinement of the study protocol and approved the final manuscript. GHG is the principal investigator of the study.

#### Funding: None

Competing interests: None<u>declared</u>

**Ethics approval:** The protocol has been approved by Hamilton Integrated Research Ethics Board (HIREB13-506)

**Provenance and peer review:** Not commissioned; internally peer reviewed.


**Open Access:** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http:// creativecommons.org/licenses/by-nc/3.0/.

#### **Reference:**

- 1. Woolf, A.D. and B. Pfleger, *Burden of major musculoskeletal conditions*. Bull World Health Organ, 2003. **81**(9): p. 646-56.
- 2. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum, 2000. **43**(9): p. 1905-15.
- 3. Brandt, K.D., *Non-surgical treatment of osteoarthritis: a half century of "advances".* Ann Rheum Dis, 2004. **63**(2): p. 117-22.
- 4. Rath, E., O. Tsvieli, and O. Levy, *Hip arthroscopy: an emerging technique and indications.* Isr Med Assoc J, 2012. **14**(3): p. 170-4.
- 5. Chen, A., et al., *The Global Economic Cost of Osteoarthritis: How the UK Compares.* Arthritis, 2012. 2012: p. 698709.
- 6. Kurtz, S., et al., *Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030.* J Bone Joint Surg Am, 2007. **89**(4): p. 780-5.
- 7. *7th annual report*, in *National Joint Registry for England and Wales*. 2010, National Joint Registry: Hemel Hempstead.
- 8. Kenney, N.A. and K.W. Farmer, *Minimally invasive versus conventional joint arthroplasty.* PM R, 2012. **4**(5 Suppl): p. S134-40.
- 9. DK, M. *Hip arthroscopy: Update, advances, and future applications.* AAOS Now, 2011. **5**.
- 10. Griffiths, E.J. and V. Khanduja, *Hip arthroscopy: evolution, current practice and future developments.* Int Orthop, 2012. **36**(6): p. 1115-21.
- 11. HA., L.-T., *Threshold technique.* Kattan MW, ed. Encyclopedia of Medical Decision Making. . 2009, Thousand Oaks,CA: Sage Publications. 4.
- 12. Llewellyn-Thomas, H.A., et al., *Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia.* Med Decis Making, 1996. **16**(3): p. 262-82.
- Ubel, P.A. and G. Loewenstein, *The role of decision analysis in informed consent: choosing between intuition and systematicity.* Soc Sci Med, 1997. 44(5): p. 647-56.
- 14. GW., T., Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Econ Planning Sci, 1976. **10**(129): p. 36.
- 15. Zeelenberg, M., *The use of crying over spilled milk: A note on the rationality and functionality of regret.* Philosophical Psychology, 1999. **12**(3): p. 325-340.
- 16. Zeelenberg, M., *Anticipated regret, expected feedback and behavioral decision making.* Journal of Behavioral Decision Making, 1999. **12**(2): p. 93-106.
- 17. D., K., *Maps of bounded rationality: psychology for behavioral economics.* The American Economic Review, 2003.(93): p. 1449-1475.
- 18. JSBT., E., *Hypothetical thinking: Dual processes in reasoning and judgement.* 2007, New York: Psychology Press.
- 19. I, S., The influence of anticipating regret and responsibility on
- purchase decisions. J Consumer Res, 1992. 19: p. 105-118.

1		
2		
3		
4		
5		
0		
6		
7		
8	20.	Zeelenberg M, P.R., A theory of regret regulation 1.0 J Consumer
9		ology, 2007. <b>17</b> : p. 3-18.
10		
11	21.	Tsalatsanis, A., et al., A regret theory approach to decision curve analysis: a
12		novel method for eliciting decision makers' preferences and decision-making.
		BMC Med Inform Decis Mak, 2010. <b>10</b> : p. 51.
13	22.	Bettman., J., Information processing models of consumer behavior. J Marketing
14		Res, 1970. <b>7</b> : p. 6.
15	23.	Jacob Jacoby, D.E.S., and Carol A. Kohn., Brand Choice Behavior As a Function
16	-	of Information Load: Study Ii (Abstract). Advances in Consumer Research,
17		1974. <b>01</b> : p. 3.
18	24.	Hahn, M., R. Lawson, and Y.G. Lee, <i>The effects of time pressure and information</i>
19	24.	
20	<b>.</b> -	load on decision quality. Psychology and Marketing, 1992. <b>9</b> (5): p. 365-378.
	25.	Young, D.R., D.T. Hooker, and F.E. Freeberg, Informed consent documents:
21		<i>increasing comprehension by reducing reading level.</i> IRB, 1990. <b>12</b> (3): p. 1-5.
22	26.	Comprehensive Working Group on Informed Consent in Cancer Clinical Trials
23		for the National Cancer Institute: Recommendations for the Development of
24		Informed Consent Documents for Cancer Clinical Trials 1998 [cited 2013
25		April 9th].
26	27.	OHRP Informed Consent Frequently Asked Questions 2008 [cited 2013 April
27	27.	9th]; Available from: <u>http://www.hhs.gov/ohrp/informconsfag.html</u> .
28	20	
	28.	Sharp, S.M., Consent documents for oncology trials: does anybody read these
29	•	<i>things</i> ? Am J Clin Oncol, 2004. <b>27</b> (6): p. 570-5.
30	29.	Beardsley, E., M. Jefford, and L. Mileshkin, <i>Longer consent forms for clinical</i>
31		trials compromise patient understanding: so why are they lengthening? J Clin
32		Oncol, 2007. <b>25</b> (9): p. e13-4.
33	30.	Soever, L.J., et al., Educational needs of patients undergoing total joint
34		<i>arthroplasty.</i> Physiother Can, 2010. <b>62</b> (3): p. 206-14.
35	31.	Alonso-Coello, P., et al., Evaluating patient values and preferences for
36	-	thromboprophylaxis decision making during pregnancy: a study protocol. BMC
37		Pregnancy Childbirth, 2012. <b>12</b> : p. 40.
	32.	Monsivais, D. and A. Reynolds, <i>Developing and evaluating patient education</i>
38	52.	
39		<i>materials.</i> J Contin Educ Nurs, 2003. <b>34</b> (4): p. 172-6.
40	33.	Schunemann, H.J., et al., A comparison of narrative and table formats for
41		presenting hypothetical health states to patients with gastrointestinal or
42		pulmonary disease. Med Decis Making, 2004. 24(1): p. 53-60.
43	34.	Informed Medical Decisions Foundations 2013; Available from:
44		http://www.informedmedicaldecisions.org/
45	35.	Pierce, L.L., How to choose and develop written educational materials. Rehabil
46		Nurs, 2010. <b>35</b> (3): p. 99-105.
	36.	Aldridge, M.D., Writing and designing readable patient education materials.
47	50.	Nephrol Nurs J, 2004. <b>31</b> (4): p. 373-7.
48	27	
49	37.	Turnbull, A., <i>How nurses can develop good patient information leaflets.</i> Nurs
50		Times, 2003. <b>99</b> (21): p. 26-7.
51	38.	Stevens, M.S., et al., The evidence for hip arthroscopy: grading the current
52		<i>indications.</i> Arthroscopy, 2010. <b>26</b> (10): p. 1370-83.
53		
54		
55		
		23
56		
57		
58		

- 39. McCarthy, J.C., et al., *What factors influence long-term survivorship after hip arthroscopy?* Clin Orthop Relat Res, 2011. **469**(2): p. 362-71.
- 40. Green, C., J. Brazier, and M. Deverill, *Valuing health-related quality of life. A review of health state valuation techniques.* Pharmacoeconomics, 2000. **17**(2): p. 151-65.
- 41. G.Bluman, A., *Elementary Statistics: A step by step approach*. fifth edition ed. 2010: McGraw Hill.
- 42. Blalock, H.M., *Social Statistics*. 1979, New York: McGraw-Hill.
- 43. Cohen, J., *A power primer*. Psychol Bull, 1992. **112**(1): p. 155-9.
- 44. Hawker, G.A., *Who, when, and why total joint replacement surgery? The patient's perspective.* Curr Opin Rheumatol, 2006. **18**(5): p. 526-30.
- 45. Vandenbroucke, J.P., et al., [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. Gac Sanit, 2009. **23**(2): p. 158.
- 46. Tfelt-Hansen, P.C., *CONSORT recommendations in abstracts of randomised, controlled trials on migraine and headache.* J Headache Pain, 2011. **12**(5): p. 505-10.
- 47. Alolabi, B., et al., *The development of a decision aid to elicit treatment preferences for displaced femoral neck fractures.* Indian J Orthop, 2012. **46**(1): p. 22-8.
- 48. Bryant, D., E. Bednarski, and A. Gafni, *Incorporating patient preferences into orthopaedic practice: should the orthopaedic encounter change?* Injury, 2006.
  37(4): p. 328-34.
- 49. *Distributed decision making: the anatomy of decisions-in-action.* Sociol Health Illn, 2008. **30**(3): p. 429-44. doi: 10.1111/j.1467-9566.2007.01064.x. Epub 2008 Jan 11.
- 50. Vieder, J.N., et al., *Physician-patient interaction: what do elders want?* J Am Osteopath Assoc, 2002. **102**(2): p. 73-8.
- 51. D., T., Congenital dysplasia and dislocation of the hip in children and adults. 1987, New York: Springer



Imagine that you have chosen to have 100, how much would you regret end up needing hip replacemen	your choice of arthroscopy if you
No regret	Maximum regret
0	100
<	$\longrightarrow$


Patient's regret in scale 0-100 (0=no regret, 100=maximum regret)

Regret (0-100)

205x131mm (300 x 300 DPI)

**BMJ Open** 

## Appendix: Script #1: Health scenarios





## Introduction

Hip arthroscopy is a surgical procedure that gives doctors a clear view of the inside of the hip joint. This helps them diagnose and treat joint problems. The surgeon will make small cuts around your hip and look inside using a tiny camera. Other medical instruments may also be used inside to fix your hip. Patients with Osteoarthritis and hip pain who do not respond to conservative treatment and have no evident cause on standard radiographs, might be candidates for a hip arthroscopy. Arthroscopy has also been used to diagnose and evaluate other diseases affecting the hip, such as Femoroacetabular Impingement, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Perthes Disease, Synovial Chondromatosis, and Ankylosing Spondylitis of the hip.

## Procedure:







- Hip arthroscopy is performed through small incisions (about 0.5 to 1cm in length each) using a camera to visualize the inside of the hip joint.
- The tiny camera splits the muscle fibers. When the camera is removed, the muscle fibers return to their normal position and alignment.
- Surgeons will be able to see the joint through the camera, identify the problem(s), and
  - Repair torn cartilage
  - Remove loose pieces of cartilage, bone or ligaments
  - Reshape the bones
- > The operation typically takes 60-90 minutes.

## **Benefits:**


- Arthroscopy can potentially delay the need for Total Hip Replacement surgery in the future.
- Minimally invasive procedure: You will have very small incisions (0.5-1cm in length each, two to four in total) around the hip.
- Outpatient procedure: You usually go home the same day that you have surgery.
- Short rehabilitation period: On the first day after surgery, you will begin the rehabilitation process. This includes getting out of bed and walking. You may be able to bear some weight on the treated leg right away.

1	
2	
3 4	You will have greater chance of going back to play competitive
5	sports and a high functional level compare to total hip
6	replacement surgery.
7	
8	Early return to sport: Most patients find they are back to full
9	activities 3-4 months following hip arthroscopy.
10	Decovery
11	<u>Recovery:</u>
12 13	Management:
13	
15	<ul> <li>You may have some pain and discomfort following your surgery. You</li> </ul>
16	will be given a prescription for pain medication which can be taken as
17	needed.
18	
19	• You will need to leave the patches on your wound and keep it dry for
20	24 hours.
21 22	
22	Rehabilitation:
24	• You can have protected weight bearing (weight bearing as
25	tolerated with crutches) immediately following surgery.
26	
27	• You will need to begin physiotherapy as early as 48 hours
28	after surgery with the guidance of your physiotherapist.
29	• The rehabilitation will involve exercises to improve range of
30 31	motion of the hip as well as strengthening exercises.
32	motion of the mp as well as strengthening exercises.
33	• Your physiotherapist will help you decide when and how to
34	progress your exercises in the long run.
35	It is more incompared that more still and something from the first
36	$\circ$ It is very important that you will use crutches for the first
37	two weeks after surgery to help protect the repair and
38	improve gait mechanics following surgery
39 40	• You may require assistance with driving for up to 6 weeks.
41	
42	<ul> <li>Exercises like stationary bike are a part of the rehab and</li> </ul>
43	may begin as soon as 48 hours after surgery.
44	• Sedentary work can be partially resumed in one to two weeks.
45	
46	Labor-intensive work may require 3 months.
47 48	• You can resume full physical activity in 3 to 6 months
49	depending on your goals.
50	
51	Possible Risks and complications:
52	Hip arthroscopy appears to be safe. The overall complication rate with
53	hip arthroscopy was 4 in 100 (4.0%) with the vast majority of
54	complications being non-life or limb threatening in nature. Here are
55 56	
56 57	rare complications that can occur:
58	
59	

- Neurologic traction injury: About 3 in 1000(0.3%) of you will experience it.
  - This is the least severe form of nerve injury.. The actual structure of the nerve remains intact, but there is a transient interruption in the sensations being conducted through the injured nerve fiber. You could have decreased feeling or loss of strength in the skin on the lateral part of your leg and genital area, but there is usually a complete recovery.
- Intra-abdominal Fluid Extravasations: About 15 in 10,000(0.15%) of you will experience it.
  - During the procedure, when fluid is removed from the hip joint by the arthroscopy, some fluid may leak into the abdomen. You could experience the sense of increased abdominal pressure and discomfort that involves a measurable change in the circumference of your abdomen sometimes with swollen legs.
- Dislocation of the hip: About 3 in 10,000(0.03%) of you will experience it.
  - You could experience sharp, pain that become worse if the joint has moved. These symptoms will last until the damaged tissue has been allowed to rest and heal completely, and will require use of painkillers. Your orthopedic surgeon will have to pull on the leg to reposition the hip within the socket under anesthesia.
- Blood clots in the legs or pelvis: About 6 in 10,000 (0.06%) of you will experience it during the first 6 months.
  - The blood clot, due to immobilization, causes pain and swelling in the affected leg that typically gets better in about a month. About 17% to 50% of you will have persisting leg swelling, pain, vein swelling, and skin induration, for a longer period, up to 2 years.





# Arthroscopy for Hip Osteoarthritis



# Introduction

Hip arthroscopy is a surgical procedure that gives doctors a clear view of the inside of the hip joint. This helps them diagnose and treat joint problems. The surgeon will make small cuts around your hip and look inside using a tiny camera. Other medical instruments may also be used inside to fix your hip. Patients with Osteoarthritis and hip pain who do not respond to conservative treatment and have no evident cause on standard radiographs, might be candidates for a hip arthroscopy. Arthroscopy has also been used to diagnose and evaluate other diseases affecting the hip, such as Femoroacetabular Impingement, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Perthes Disease, Synovial Chondromatosis, and Ankylosing Spondylitis of the hip.





## **Procedure:**

- The hip joint is made up of two major parts. The hip joint is a ball and socket joint that not only allows flexion and extension, but also rotation of the thigh and leg.
  - The hip **socket**, which is cup-shaped, sits in the pelvis.
  - The **ball** is the upper end of the thighbone (called the femoral head).
- If you would like to sleep during the surgery, the anesthetist will put you to sleep, so you will not be awake and therefore will have no memory of the procedure.
- $\succ$  Anesthesia:
  - There are two anesthesia options for this procedure, you can either have a general or a regional (spinal) anesthetic. Both options are safe and your pain will be managed with both.
  - General anesthesia: you will be 'asleep' (unconscious) for the procedure and not have any memory of the surgery.
  - Regional anesthesia: local anesthesia will be put in your lower back to make your body numb so you won't feel the procedure. Although you will still be awake and aware of the procedure the anesthesiologist can give you sedation medication to make you quite sleepy so you aren't anxious and mostly unaware of the procedure.
- After you receive anesthesia, your surgeon will put your leg in traction.

#### **BMJ Open**

2	
3	• This means that your hip will be pulled away from the
4 5	socket enough for your surgeon to insert instruments, see
6	the entire joint, and perform the treatments needed.
7	
8	• The bones of the hip joint (the ball and socket) are
9	separated by approximately 1cm by applying traction to the
10	foot while wearing a special boot.
11 12	
13	Initially, air and/or fluid are injected into the hip, under x-ray
14	guidance. Once correct placement of the instrument has been
15	confirmed typically small incisions are made around the hip.
16	> Each of these incisions generally are approximately 0.5 to 1 cm in
17	
18	length.
19 20	Through these small holes, the tiny camera ('arthroscope') and
20	instruments are passed into the joint under x-ray guidance.
22	
23	> The tiny camera will split the muscle fibers. When the camera is
24	removed, the muscle fibers return to their normal position and
25	alignment.
26	Surgeons will be able to see the joint through the camera and
27 28	identify the problems. Depending on the problem encountered,
28 29	
30	your surgeon will perform the appropriate procedures such as:
31	<ul> <li>Repair torn cartilage</li> </ul>
32 33	<ul> <li>Remove loose pieces cartilage, bone or ligaments</li> </ul>
34 35	• Reshape the bones
36	The operation typically takes 60-90 minutes but duration will
37	vary depending on the problem in the hip joint but can last up to
38	120 minutes.
39	
40 41	After surgery, you will stay in the recovery room for 1 to 2 hours,
42	then stay in the surgery area before being discharged to go home.
43	
44	
45	Benefits:
46	Authorses an estantially delegather good for Tetal II in
47 48	Arthroscopy can potentially delay the need for Total Hip
49	Replacement surgery in the future.
50	Main possible benefits of arthroscopy compared to total hip
51	replacement:
52	• Relief of symptoms, including reduced pain.
53	<ul> <li>Functional improvement, meaning increased mobility and</li> </ul>
54	regained ability to perform activities of daily living, the
55 56	
57	extent of which depend on the severity of your OA and other
	pre-existing conditions before the surgery.

- It helps to diagnose and treat early causes of arthritis, possibly preventing progression.
- Hip arthroscopy is a minimal invasive surgery compared to the open surgical alternatives. You will have very small incisions (about 0.5-1 cm each in length, two to four in total) around the hip, leading to minimal scarring.
- Outpatient procedure: You usually go home the same day or the next day that you have surgery.
- You will have chance of going back to activity at a high functional level. For example, playing competitive sports such as soccer or hockey.
- Less restriction on physical activities than after a hip replacement: On the day after surgery, you will begin the rehabilitation process. This includes getting out of bed and walking.
- You can bear some weight on the treated leg the day after surgery.
  - You will be able to ride the stationary bike 48 hours after your surgery.
- Early return to physical exercise: Most likely you will go back to full activities 3 to 6 months following hip arthroscopy.
  - One to two weeks after the surgery after your wound has healed, you can walk in the pool.
  - Approximately six to eight weeks after the surgery, you maybe able to increase activities including light aerobic exercise.
  - Approximately 3-6 months after surgery, you will be able to do unrestricted exercise and recreational sports after discussion with your surgeon.
  - These sports may include soccer, football, tennis, etc.

## **Recovery:**

- > Management:
  - After hip arthroscopy your wound is covered with patches.
  - You will need to leave the patches in place and to keep your wounds dry for 24 hours.
  - You will be given a prescription for pain medication following your surgery which you will take as needed.

#### **BMJ Open**

	<ul> <li>You will be given oral or intravenous antibiotics to prevent infection and you may also be given a medication to prevent blood clots in the legs.</li> </ul>
$\succ$	Rehabilitation:
0	You are able to have protected weight bearing (weight bearing as tolerated with crutches) immediately following surgery.
0	You will need to begin physiotherapy as early as 48 hours after surgery.
0	Exercises like stationary bike are a part of the rehab and may begin as soon as 48 hours after surgery.
0	Your physiotherapist will guide you through the rehabilitation program, which will involve exercises to improve range of motion of the hip as well as strengthening exercises.
0	Your physiotherapist will help you decide when and how to progress your exercises in the long run.
0	It is very important that you use crutches for the first two weeks after surgery to help protect the repair and improve gait mechanics following surgery. The rehabilitation progress, as well as the extent of the tear and/or associated problems, will determine the weaning process.
0	Your joint can be quite sore at first, and it may need some time t settle. Therefore, you are not allowed to do movements/activities that may provoke the pain such as lifting, twisting, overstretching, and jarring.
0	You may require assistance with driving for up to 6 weeks.
0	In most occupations, such as sedentary job, you will be able to return to work in one to two weeks. However, since the return at this point will not be completely normal you may need some breaks in between. You may not be able to work the whole day, but you can be productive.
0	If your job requires significant manual labor and lifting, the return may not occur completely until at least three months following surgery. A discussion with your surgeon may be needed too.
0	Full physical activity will resume up to 3 to 6 months depending on your goals.
Risk	s and complications:

Hip arthroscopy appears to be safe. Although about 4 in 100 (4%) of you may present some kind of complication, most of the complications are not life or limb threatening.


- Neurologic traction injury: About 3 in 1000 (0.3%) of you will experience neurologic traction injury
  - This is the least severe form of nerve injury. The actual structure of the nerve remains intact, but there is a transient interruption in the sensations being conducted through the injured nerve fiber. You could have decreased feeling or loss of strength in the skin on the lateral part of your leg and genital area, but there is usually a complete recovery.
  - Most commonly, numbress will go away within a week or so. In some cases, smaller areas may continue to be numb for several weeks.
- Intra-abdominal fluid collections: About 15 in 10,000 (0.15%) of you will experience fluid collections
  - During the procedure, when fluid is removed from the hip joint by the arthroscopy, some fluid may leak into the abdomen. You could experience the sense of increased abdominal pressure and discomfort that involves a measurable change in the circumference of your abdomen sometimes with swollen legs.
- Dislocation of the hip: About 3 in 10,000 (0.03%) of you will experience dislocation during the first 6 months
  - You could experience sharp, pain that become worse if the joint has moved. These symptoms will last until the damaged tissue has been allowed to rest and heal completely, and will require use of painkillers. Your orthopedic surgeon will have to pull on the leg to reposition the hip within the socket under anesthesia.
- Blood clots in the legs or pelvis: About 6 in 10,000 (0.06%) of you will experience blood clot during the first 6 months.
  - The blood clot, due to immobilization, causes pain and swelling in the affected leg that typically gets better in about a month. About 17-50% of you will have persisting leg swelling, pain, vein swelling, and skin induration, for a longer period, up to 2 years.

4

# **Total Hip Replacement for Hip Osteoarthritis**

## **Introduction**

Hip replacement is a surgery that aims to relieve arthritis pain. stabilize and improve the function of your hip. The most common cause for the pain is osteoarthritis (OA). Cartilage, which is the rubbery tissue that cushions your bones and joints, can break down and wear away. As a result, the bones rub together, causing pain, swelling, and stiffness.



\*ADAM

The surgeon will remove the old hip joint and put in a new joint. If other treatments such as physical therapy, pain medicines, and exercise have not helped, then hip replacement surgery might be an option for you.

## **Procedure:**

- The anesthetist will put you to sleep if you request it, and you will not feel any pain during surgery.
- After you receive anesthesia, your surgeon will open up your hip joint and does the following:
  - Removes the damaged ball from the thighbone and cleans out the socket.
  - Replaces the natural joint with an artificial ball and socket.
- > The surgery usually takes 1 to 3 hours.

## **Benefits:**

➢ Main benefit:

A metal ball and stem are inserted in the femur and a plastic socket is placed in the enlarged pelvis cup



\*ADA.N

- Relief of symptoms, including reduced pain, increased mobility and/or regained ability to perform activities of daily living.
- The above improvements depend on the severity of your OA and other preexistent diseases.
- > Post-operative mobility:
  - Most of you will have an increased range of movement 3 months after surgery. About 51 in 100 (51%) of you will not need an aid to walk and will be able to move your hip more than 160 degrees.
  - About 77 in 100 (77%) of you will be able to walk without support, 21 in 100 (21%) will use a cane, and 2 in 100 (2%) will use crutches (Data from patients average age of 80; range, 56-98 years old) after 1 to 2 years.
- > Pain relief:

- About 87 to 91 in 100 (87%-91%) of you will have great or complete pain relief, and 9 to 13 in 100 (9%-13%) of you will experience an unfavorable long-term joint pain after the procedure from 3 months to 5 years (Data from patients average age of 69 years old).
- > Sleep:
  - Your sleeping quality will improve significantly 10 weeks after surgery.
- Determinants regarding home management, mobility, and work will considerably improve after 3 months.

## Recovery:

- > Management:
  - You may have great deal of pain requiring painkillers within the first days.
  - You may have some pain for up to 2-3 weeks and the pain may persist for 3 months.

## Rehabilitation:

- You will have severe mobility restrictions and the types of restriction will depend on the specific procedure of your surgery. You will need a walker for the first days to weeks; then a cane or crutches for weeks up to 3-6 months.
- You will not be able to bend your hip over 90 degrees for 3 months.
- Physical therapy is an important part of the recovery process. You will work with a physical therapist to develop an exercise and rehabilitation program while your stay in the hospital.

1	
2	
3	
4	<ul> <li>The rehabilitation program generally includes exercises to</li> </ul>
5	stretch and strengthen the muscles surrounding the hip joint, as
6	well as training in activities of daily living.
7	
	<ul> <li>Most of you will be able to resume your activities of daily living</li> </ul>
8	within 3 to 6 months.
9	
10	Long-term outlook:
11	
12	
13	➢ 90 out of 100(90%) of your hip replacements will last longer than 10
14	years.
15	* 85 out of 100(85%) of your hip replacements will last longer than 20
16	
17	years.
18	➢ Over the course of 15 to 20 years, the artificial hip joint will loosen and
19	you may need a second replacement.
20	you may nood a socona replacement.
21	Possible Ricks and complications:
22	Possible Risks and complications:
23	
24	▶ In 6 months post operation, about 30 in 100 (30%) of you will have at
25	least one complication.
26	
27	While some complications can be a bit more serious, most can be
28	treated successfully.
29	▶ Urine retention: About 20 to 35 in 100 of you (20-35%) will experience
30	it.
31	16.
32	➢ Infections: About 1 in 100 of you (1%) will develop a wound or deep
33	
34	infection after the operation.
35	➢ Death: 3 out of 1000(0.3%) will die.
36	$\rightarrow$ Death. 5 out of 1000(0.5/0) will ulc.
37	Blood clots in the legs or pelvis: About 5 in 1000 (0.5%) of you may
38	experience it before hospital discharge.
39	experience it before nospital discharge.
40	$\circ$ The blockage causes pain and swelling in the affected leg that
41	
42	typically gets better in about a month.
43	Blood alots in the lunger About 0 in 1000(0.00/) during the first 0
44	Blood clots in the lungs: About 9 in 1000(0.9%) during the first 6
45	months.
46	
47	$\circ$ This leads to shortness of breath, sometimes severe, which with
48	anticoagulant treatment resolves in about 2 weeks. Anticoagulant
49	treatment will be used for 3 months.
50	
51	$\blacktriangleright$ Dislocation of the hip: About 4 in 100(4%) at the first 6 months.
52	-
53	<ul> <li>You could experience sharp, pain that become worse if the joint</li> </ul>
53 54	has moved. Your orthopedic surgeon will pull on the leg to
	reposition the hip within the socket under anesthesia.
55 56	reposition the hip within the source under anesthesia.
56	Norma damages About 1 to $2 in 100 (10/200)$
57	Nerve damage: About 1 to 3 in 100 (1%-3%).
58	
59	
60	

- If there is nerve damage, you will have decreased feeling or loss of strength in the leg, foot or ankle area.
- $\geq$ Different leg lengths: Less than 1 in 100(1%) of you will need another operation because one leg is longer than the other.

For beer terrier only

4 5 6

7

8

9

10

11

12

13

14 15

16

17

18

19

20

21

22

23

24

25 26

27

28

29 30

31 32

33

34

35

36 37

38

39

40

41 42

43

44

45

46 47

48

49

50

51

52 53

54

55

# **Total Hip Replacement for Hip Osteoarthritis**

## Introduction

Hip replacement is a surgery, also called Total Hip Arthroplasty,

which aims to relieve arthritis pain, improve function, and make your hip more stable. The most common cause for the pain is osteoarthritis (OA), and the reason for OA unknown. is Cartilage, which is the rubbery tissue that cushions your bones and joints, can break down and wear away. As a result, the bones together. rub causing pain. swelling, and stiffness. During the operation, the surgeon will remove the old hip joint and put in a new joint. If other treatments such as



\*ADAM

physical therapy, pain medicines, and exercise have not helped, then hip replacement surgery might be an option for you.

### Procedure

- The hip joint is made up of two major parts. One or both parts may be replaced during surgery.
  - The hip **socket**, which is cup-shaped, and sits in the pelvis.
  - The **ball**, which is the upper end of the thighbone (called the femoral head).
- > The new hip that replaces the old one is made up of these parts:
  - A socket, which is usually made of strong metal.
  - A liner, which fits inside the socket and usually, is made of either plastic, ceramic, or metal.
  - A metal or ceramic ball that will replace the top of your thighbone.
  - A metal stem that is attached to the thighbone to make the joint more stable.
- If you would like to sleep during the surgery, the anesthetist will put you in sleep, and you will not feel any pain during surgery.
- $\succ$  Anesthesia:
  - You will not feel any pain during surgery due to one of two types of anesthesia that you will receive
  - General anesthesia: you will be 'asleep' (unconscious) for the procedure and not have any memory of the surgery.

- Regional anesthesia: local anesthesia will be put in your lower back to make your body numb so you won't feel the procedure. Although you will still be awake and aware of the procedure the anesthesiologist can give you sedation medication to make you quite sleepy so you aren't anxious and mostly unaware of the procedure.
- After you receive anesthesia, your surgeon will make a surgical cut to open up your hip joint. Then you surgeon will:
  - Cut and remove the head of the thighbone.
  - Clean out your hip socket and remove the rest of the cartilage and damaged bone.
  - Put the new hip socket in place, then insert the metal stem into your thighbone.
  - Place the correct-sized ball for the new joint.
  - Secure all parts with cement.
  - Repair the muscles and tendons around the new joint.
  - Close the surgical cut.
- The surgery usually takes 1 to 3 hours.

A metal ball and stem are inserted in the femur and a plastic socket is placed in the enlarged pelvis cup



(MedlinePlus, 2012)

\*ADAM

## **Benefits**

- ➢ Main benefit:
  - Relief of symptoms, including reduced pain, increased mobility and regained ability to perform activities of daily living.
  - Function improvement and pain relief are depending on the severity of your OA and other preexistent diseases.
- Mobility postoperatively:
  - Most of you will have an increased range of movement 3 months after surgery. About 51 in 100 (51%) of you will not need assistance to walk and will be able to move your hip more than 160 degrees.
  - About 49 in 100 (49%) of you will require assistance to walk and will be able to move your hip less than 160 degrees after 3 months.
  - About 64 in 100 (64%) of you will be able to walk longer distances compare to pre-operatively after 3 months (Data from patients age 55-84 years old).

1 2			
2 3 4 5 6 7 8		0	About suppo use cr years
9 10	$\triangleright$	Pain	relief:
11 12 13 14 15 16 17		0	About compl experi proced patier
18 19 20 21		0	About month
22	$\triangleright$	Sleep	:
23 24 25 26		0	Your s surge
27 28 29 30 31 32	>	Psych o	ologica Your j intera behav
33 34 35	$\triangleright$		rs such lerably
36 37 28	<u>Reco</u>	very:	
38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55			gemen After the fin You m (patie You m persis You a paink You w You m stocki
55 56 57 58 59 60	×	o Rehal	You w restrie

- 77 in 100 (77%) of you will be able to walk without rt, 21 in 100 (21%) will use a cane, and 2 in 100 (2%) will utches (Data from patients average age of 80; range, 56-98 old) after 1 to 2 years.
- 87 to 91 in 100 (87%-91%) of you will have great or ete pain relief, and 9 to 13 in 100 (9%-13%) of you will ence an unfavorable long-term joint pain after the dure from 3 months to 5 years follow-up (Data from nts average age 69 years).
- 25 in 100 (25%) of you will only have occasional pain 3 ns after operation.
- sleeping quality will improve significantly 10 weeks after ry.
- al improvements:
  - psychosocial quality of life will improve regarding social ction, communication, alertness behavior, and emotional ior immediately and 6 months after the operation.
- as home management, mobility, and work will improve after 3 months.
- t:
  - surgery, you may experience a great deal of pain within est days and you may need to take painkillers.
  - nay be given pain medication intravenously using a pump nt-controlled-analgesia).
  - nay have some pain for up to 2-3 weeks and the pain may st for 3 months.
  - re likely to have problems with constipation from illers in the first weeks after surgery.
  - ill be given an antibiotic to prevent infection.
  - nay also be given a medication or compression boots and ngs to prevent blood clots in the legs.
- on:
  - ill have severe mobility restrictions and the types of ction will depend on the specific procedure of your surgery.

4

5 6

7

8

9

10

11 12

13

14

15

16 17

18

19

20

21 22

23

24

25

26 27

28

29

30

31

32 33

34

35

36

37 38

39

40

41

42

43 44 45

46

47

48

49 50

51

52

53 54

55

56 57

58 59 60

You will need a walker for the first days to weeks; then a cane or crutches for weeks to 3-6 months. 0 You will not be able to bend your hip over 90 degrees for 3 months. This means you cannot bring your knee up to your chest and you also cannot bend forward at the hip past 90 i.e. if tying your shoes. You may also have restricted adduction (moving your leg past 0 midline) and any twisting (internal/external rotation) of the leg. Your surgeon will determine the timeline for these restrictions. 0 You will also have difficulties for dressing and need for 0 mechanical aids. Physical therapy is an important part of the recovery process. 0 The length of stay in the hospital for most of you will be about 1 to 3 days, during which time you will work with a physical therapist to develop exercises and follow a rehabilitation program. • You may need physiotherapy up to 3 month depending on your condition. The rehabilitation program generally includes exercises to 0 stretch and strengthen the muscles surrounding the hip joint, as well as training in activities of daily living, such as stair climbing, and walking. Most of you will be able to resume your activities of daily living 0 within 3 to 6 months. Your ability to perform household, domestic tasks (for example 0 cutting toenails, having a bath, climbing stairs) will improve. About 84 in 100 (84%) of you will be able to maintain your own 0 home, 6 in 100 (6%) of you will live at home with assistance, and only 10 in 100 (10%) will need someone to take care of you fulltime 20 years after operation (Data from patients average age 80 years; range, 56-98 years). You might be able to return to recreational sports after 6 months after discussion with your surgeon. Long-term Outlook: About 90 out of 100 (90%) of your hip replacement will last longer than 10 years. > About 85 out of 100 (85%) of your hip replacements will last longer than 20 years. > Over the course of 15 to 20 years, the artificial hip joint will loosen and you may need a second replacement. **Risks and complications:** ➢ 6 months post operation, about 30 in 100 (30%) of you will have at least one complication.

2	
3	
4	
5	
3 4 5 6 7	
0	
1	
8	
9	
10	
11	
12	
12	
13	
14	
15	
16	
17	
18	
8 9 10 11 12 13 14 15 16 17 18 19 20	
19	
20	
21	
22	
21 22 23 24 25 26 27 28 29	
24	
25	
20	
20	
27	
28	
29	
30 31	
31	
22	
32 33 34 35 36 37 38	
33	
34	
35	
36	
37	
20	
30	
39	
40	
41	
42	
43	
44	
44 45	
46	
47	
48	
49	
50	
50	
52	
53	
54	
55	
56	
50	
58	
59	
60	

- While some complications can be a bit more serious, most can be treated successfully, such as blood clots.
  - ▶ Urine retention: About 20 to 35 in 100(20-35%) of you will experience it.
    - > You may urinate frequently; you may feel an urgent need to urinate but have little success when you get to the toilet; or you may feel you still have to go after you've finished urinating.
- ➤ Infections: About 1 in 100 (1%) of you will develop an infection after the operation.
- It may occur in the wound or deep around the artificial implants.
  Deep joint infection: 2 in 1000(0.2%) in first 90 days.
  - You will experience fever or chills due to the infection, unusually swelling of the hip joint. The replaced hip will be removed, and you will be without a hip joint and receiving antibiotics for months.
- Risk of a complication will be higher if you have other diseases. For instance, 40-50 in 100 (40-50%) of you who have at least three other conditions, such as heart disease, urinary tract infection, or obesity will experience a complication.
- Death: 3 out of 1000(0.3%) of you who undergo hip replacement surgery will die.
- Blood clots in the legs or pelvis: About 5 in 1000 (0.5%) before hospital discharge.
  - The blood clot, due to immobilization, causes pain and swelling in the affected leg that typically gets better in about a month. About 17% to 50% of you will have persisting leg swelling, pain, vein swelling, and skin induration, for a longer period, up to 2 years.
  - If you are older, overweight, have cancer, or have experienced blood *clots before, you will be more likely to get blood clots after surgery*.
  - This clot can potentially lead to another complication, which is localized swelling in the leg due to clot and decreased flow of blood to the heart.
- Dislocation of the hip: About 1 in 100 (1%) of you will have dislocated the hip by first week, 3 in 100 (3%) by eighth week, and about 4 in 100(4%) at the first 6 months
  - You could experience sharp, pain that become worse if the joint has moved. These symptoms will last until the damaged tissue

has been allowed to rest and heal completely, and will require use of painkillers. Your orthopedic surgeon will have to pull on the leg to reposition the hip within the socket under anesthesia.

> Nerve damage: 1 to 3 in evey 100 (1%-3%) of you.

- If there is nerve damage, you will have decreased feeling or loss of strength in the leg, foot or ankle area. Around 0.5% of you will have the nerve damage permanently.
- Different leg lengths: Less than 1 in 100(1%) of you will need another operation because one leg is longer than the other.
  - You might need another surgery because the difference length of your legs will cause severe post surgery problems such as walking difficulty, pain, or dislocation.